Cat. No.: HY-15141

Staurosporine

(Synonyms: Antibiotic AM-2282; STS; AM-2282)

214 Cited Publications

Customer Review

Based on 214 publication(s) in Google Scholar

Staurosporine is a potent, ATP-competitive and non-selective inhibitor of protein kinases with IC₅₀s of 6 nM, 15 nM, 2 nM, and 3 nM for PKC, PKA, c-Fgr, and Phosphorylase kinase respectively. Staurosporine also inhibits TAOK2 with an IC₅₀ of 3 μM. Staurosporine is an apoptosis inducer.

For research use only. We do not sell to patients.

Purity: 99.52%
CAS No.: 62996-74-1
Formula: C₂₈H₂₆N₄O₃
Molecular Weight:466.53

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Staurosporine Chemical Structure

CAS No.: 62996-74-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (214)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

PKC

6 nM (IC₅₀)

PKA

15 nM (IC₅₀)

c-Fgr

2 nM (IC₅₀)

Phosphorylase kinase

3 nM (IC₅₀)

S6 kinase (70 kDa)

5 nM (IC₅₀)

v-Src

6 nM (IC₅₀)

cdc2

9 nM (IC₅₀)

TPK-IIB/Syk

16 nM (IC₅₀)

Ca²⁺/CaM PK-I1

20 nM (IC₅₀)

MLCK

21 nM (IC₅₀)

61 nM (IC₅₀)

EGF-R

100 nM (IC₅₀)

ERK-1

1500 nM (IC₅₀)

CSK

2000 nM (IC₅₀)

IGF-IR

6150 nM (IC₅₀)

CK2

19500 nM (IC₅₀)

CK1

163500 nM (IC₅₀)

All PKC Isoforms :

All PKA Isoforms :

All Antibiotic Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
518A2	IC₅₀	0.2 μM Compound: STP	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 24361521]
518A2	EC₅₀	0.03 μM Compound: STS	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 29197730]
8505C	IC₅₀	0.2 μM Compound: STP	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	[PMID: 24361521]
A2780	IC₅₀	0.2 μM Compound: STP	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 24361521]
A2780	EC₅₀	0.12 μM Compound: STS	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 29197730]
A2780	EC₅₀	0.1 μM Compound: STS	Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
A2780	IC₅₀	0.1 μM Compound: ST	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32422522]
A2780	EC₅₀	0.1 μM Compound: Staurosporine	Cytotoxicity against human A2780 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 33049606]
A-375	IC₅₀	2.1 μM Compound: Staurosporine	Antiproliferative activity against human A-375 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay Antiproliferative activity against human A-375 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay	[PMID: 35196017]
A-431	IC₅₀	70 nM Compound: Staurosporine	Cytotoxicity against human A431 cells after 24 hrs using Annexin VeFITC/propidium iodide staining by MTT assay Cytotoxicity against human A431 cells after 24 hrs using Annexin VeFITC/propidium iodide staining by MTT assay	[PMID: 22541051]
A549	GI₅₀	2.4 nM Compound: staurosporine	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B method Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B method	[PMID: 18484775]
A549	IC₅₀	139.95 ng/mL Compound: Staurosporine	Cytotoxicity against human A549 cells after 24 hrs by propidium iodide assay Cytotoxicity against human A549 cells after 24 hrs by propidium iodide assay	[PMID: 19138858]
A549	IC₅₀	139.95 ng/mL Compound: Staurosporine	Cytotoxicity against human A549 cells after 24 hrs by YO-PRO-1 assay Cytotoxicity against human A549 cells after 24 hrs by YO-PRO-1 assay	[PMID: 19138858]
A549	IC₅₀	0.6 μM Compound: STP	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 24361521]
A549	IC₅₀	3.05 μM Compound: Staurosporine	Antiproliferative activity against human A549 cells after 24 to 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 24 to 48 hrs by CCK-8 assay	[PMID: 24792811]
A549	IC₅₀	0.02 μM Compound: staurosporine	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 25825934]
A549	EC₅₀	0.04 μM Compound: STS	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 29197730]
A549	IC₅₀	13.22 μM Compound: Staurosporine	Antiproliferative activity against human A549 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay Antiproliferative activity against human A549 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay	[PMID: 31794211]
A549	IC₅₀	7.47 μM Compound: Staurosporine	Antiproliferative activity against human A549 cells measured after 72 hrs under normoxic condition by MTT assay Antiproliferative activity against human A549 cells measured after 72 hrs under normoxic condition by MTT assay	[PMID: 31794211]
A549	IC₅₀	9.5 μM Compound: Staurosporine	Cytotoxicity against human A549 cells assessed as cell viability measured by MTT assay Cytotoxicity against human A549 cells assessed as cell viability measured by MTT assay	[PMID: 34246754]
A549	IC₅₀	9.1 μM Compound: Staurosporine	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay	[PMID: 35196017]
A549	IC₅₀	0.002 μM Compound: Staurosporine	Anticancer activity against human A549 cells harboring KRAS mutant assessed as inhibition of cell growth Anticancer activity against human A549 cells harboring KRAS mutant assessed as inhibition of cell growth	[PMID: 38199330]
A549	IC₅₀	0.02 μM Compound: Staurosporine	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	10.1039/C2MD20098H
A549	IC₅₀	0.02 μmol Compound: Staurosporine	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	10.1039/C2MD20098H
B16-F10	IC₅₀	2.82 μM Compound: Staurosporine	Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay	[PMID: 22503364]
BGC-823	EC₅₀	26.83 μg/mL Compound: Staurosporine	Antiproliferative activity against human BGC823 cells after 48 hrs by MTT assay Antiproliferative activity against human BGC823 cells after 48 hrs by MTT assay	[PMID: 21889345]
BGC-823	IC₅₀	6.83 μM Compound: Staurosporine	Antiproliferative activity against human BGC823 cells after 48 hrs by MTT method Antiproliferative activity against human BGC823 cells after 48 hrs by MTT method	[PMID: 23018096]
BGC-823	IC₅₀	0.38 μM Compound: Staurosporine	Cytotoxicity against human BGC823 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay Cytotoxicity against human BGC823 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay	[PMID: 24328283]
BJ	IC₅₀	0.002 μM Compound: Staurosporine	Cytotoxicity against human BJ cells after 72 hrs by Calcein AM assay Cytotoxicity against human BJ cells after 72 hrs by Calcein AM assay	[PMID: 22921081]
BJ	EC₅₀	<2 μM Compound: Staurosporine	Cytotoxicity against human BJ cells Cytotoxicity against human BJ cells	[PMID: 25316317]
BJ	EC₅₀	>40 μM Compound: STS	Antiproliferative activity against human BJ cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human BJ cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30840453]
BT-549	IC₅₀	0.08 μM Compound: Staurosporine	Cytotoxic activity against human BT549 cells incubated for 24 hrs by MTT assay Cytotoxic activity against human BT549 cells incubated for 24 hrs by MTT assay	[PMID: 28705432]
CAPAN-1	IC₅₀	0.66 μM Compound: Staurosporine	Cytostatic activity against human Capan1 cells Cytostatic activity against human Capan1 cells	[PMID: 30738653]
CAPAN-1	IC₅₀	0.048 μM Compound: Staurosporine	Antiproliferative activity against human Capan1 cells Antiproliferative activity against human Capan1 cells	[PMID: 31005446]
CAPAN-1	IC₅₀	0.03 μM Compound: STS	Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
CAPAN-1	IC₅₀	0.0123 μM Compound: Staurosporine	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
CAPAN-1	IC₅₀	0.0546 μM Compound: Staurosporine	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	[PMID: 34352711]
Ca-Ski	IC₅₀	0.01144 μM Compound: Staurosporine	Antiproliferative activity against human Ca-Ski cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human Ca-Ski cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 34656041]
CCRF-CEM	IC₅₀	0.023 μM Compound: Staurosporine	Cytotoxicity against human CEM cells after 72 hrs by Calcein AM assay Cytotoxicity against human CEM cells after 72 hrs by Calcein AM assay	[PMID: 22921081]
CHO-K1	GI₅₀	0.13 μM Compound: Staurosporine	Cytotoxicity against human CHOK1 cells after 48 hrs by SRB assay Cytotoxicity against human CHOK1 cells after 48 hrs by SRB assay	[PMID: 21513294]
COLO 205	IC₅₀	<0.1 μM Compound: Staurosporine	Antiproliferative activity against human COLO205 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human COLO205 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31740249]
DLD-1	IC₅₀	0.009 μM Compound: Staurosporine	Antiproliferative activity against human colon cancer cell line (DLD-1 cells) using MTT assay Antiproliferative activity against human colon cancer cell line (DLD-1 cells) using MTT assay	[PMID: 11591505]
DLD-1	IC₅₀	0.009 μM Compound: Staurosporine	Antiproliferative activity against human DLD1 cells after 48 to 72 hrs by MTT assay Antiproliferative activity against human DLD1 cells after 48 to 72 hrs by MTT assay	[PMID: 22182929]
DU-145	IC₅₀	0.5 μM Compound: Staurosporine	Induction of mitochondrial membrane potential loss in human DU145 cells after 2 hrs by JC1 staining based fluorescence assay Induction of mitochondrial membrane potential loss in human DU145 cells after 2 hrs by JC1 staining based fluorescence assay	[PMID: 31120251]
FaDu	EC₅₀	0.2 μM Compound: STS	Cytotoxicity against human FADU cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human FADU cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
FaDu	IC₅₀	0.1 μM Compound: ST	Cytotoxicity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32422522]
FaDu	EC₅₀	0.1 μM Compound: Staurosporine	Cytotoxicity against human FaDu cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human FaDu cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 33049606]
FHC	GI₅₀	32.65 μM Compound: Staurosporine	Cytotoxicity against human FHC cells assessed as cell growth inhibition incubated for 4 days by MTT assay Cytotoxicity against human FHC cells assessed as cell growth inhibition incubated for 4 days by MTT assay	[PMID: 37506545]
HaCaT	IC₅₀	1.6 μM Compound: Staurosporine	Antiproliferative activity against human HaCaT cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay Antiproliferative activity against human HaCaT cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay	[PMID: 35196017]
HCT-116	IC₅₀	0.006 μM Compound: Staurosporine	Concentration required for growth inhibition of human colon carcinoma cell line HCT116 Concentration required for growth inhibition of human colon carcinoma cell line HCT116	[PMID: 15537345]
HCT-116	IC₅₀	39 nM Compound: Staurosporine	Inhibition of TNIK-mediated TCF4/beta-casein transcription in human HCT116 cells by beta-lactamase reporter gene assay Inhibition of TNIK-mediated TCF4/beta-casein transcription in human HCT116 cells by beta-lactamase reporter gene assay	[PMID: 23232060]
HCT-116	IC₅₀	0.055 μM Compound: Staurosporine	Cytotoxicity against human HCT116 cells by sulforhodamine B assay Cytotoxicity against human HCT116 cells by sulforhodamine B assay	[PMID: 29389122]
HCT-116	IC₅₀	0.03 μM Compound: Staurosporine	Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 30106291]
HCT-116	IC₅₀	0.037 μM Compound: Staurosporine	Antiproliferative activity against human HCT116 cells Antiproliferative activity against human HCT116 cells	[PMID: 31005446]
HCT-116	IC₅₀	<0.1 μM Compound: Staurosporine	Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31740249]
HCT-116	IC₅₀	16.15 μM Compound: Staurosporine	Antiproliferative activity against human HCT116 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay Antiproliferative activity against human HCT116 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay	[PMID: 31794211]
HCT-116	IC₅₀	8.86 μM Compound: Staurosporine	Antiproliferative activity against human HCT116 cells measured after 72 hrs under normoxic condition by MTT assay Antiproliferative activity against human HCT116 cells measured after 72 hrs under normoxic condition by MTT assay	[PMID: 31794211]
HCT-116	IC₅₀	0.04 μM Compound: STS	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
HCT-116	IC₅₀	0.0281 μM Compound: Staurosporine	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
HCT-116	IC₅₀	0.0481 μM Compound: Staurosporine	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	[PMID: 34352711]
HCT-116	IC₅₀	6.94 μM Compound: Staurosporine	Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35694689]
HCT-116	IC₅₀	32.57 μg/mL Compound: Staurosporine	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based assay	[PMID: 37224699]
HCT-116	GI₅₀	6.31 μM Compound: Staurosporine	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 4 days by MTT assay Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 4 days by MTT assay	[PMID: 37506545]
HCT-116	IC₅₀	13.2 μM Compound: Staurosporine	Antiproliferative activity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by MTT assay Antiproliferative activity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by MTT assay	10.1007/s00044-012-0306-5
HEK293	IC₅₀	0.077 μM Compound: staurosporine	Inhibition of PKC-beta II mediated IL-8 release from HEK293 cells by ELISA Inhibition of PKC-beta II mediated IL-8 release from HEK293 cells by ELISA	[PMID: 12941331]
HEK293	IC₅₀	0.077 μM Compound: Staurosporine	Inhibition of IL-8 release by HEK293 cells expressing PKC-beta2 Inhibition of IL-8 release by HEK293 cells expressing PKC-beta2	[PMID: 15771419]
HEK293	IC₅₀	0.056 μM Compound: Staurosporine	Cytotoxicity against HEK293 cells after 72 hrs by CellTiterGlo assay Cytotoxicity against HEK293 cells after 72 hrs by CellTiterGlo assay	[PMID: 24763262]
HEK293	EC₅₀	<2 μM Compound: Staurosporine	Cytotoxicity against HEK293 cells Cytotoxicity against HEK293 cells	[PMID: 25316317]
HEK293	CC₅₀	0.00354 μM Compound: Staurosporine	Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 72 hrs by CellTiter Glo luminescent assay Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 72 hrs by CellTiter Glo luminescent assay	[PMID: 28624701]
HEK293	IC₅₀	0.0037 μM Compound: Staurosporine	Cytotoxicity against human HEK293 cells assessed as cell viability incubated for 72 hrs by cell titer-glo luminescent cell viability assay (Rvb = > 100 uM) Cytotoxicity against human HEK293 cells assessed as cell viability incubated for 72 hrs by cell titer-glo luminescent cell viability assay (Rvb = > 100 uM)	[PMID: 31252285]
HEK293	IC₅₀	0.41 μM Compound: Staurosporine	Antiproliferative activity against HEK293 cells assessed as inhibition rate incubated for 72 hrs by MTT assay Antiproliferative activity against HEK293 cells assessed as inhibition rate incubated for 72 hrs by MTT assay	[PMID: 34844412]
HEK293	IC₅₀	34.33 μM Compound: Staurosporine	Cytotoxicity against human HEK293 cells assessed as inhibition of cell viability by MTT assay Cytotoxicity against human HEK293 cells assessed as inhibition of cell viability by MTT assay	[PMID: 35182815]
HEK293	GI₅₀	9.25 μM Compound: Staurosporine	Cytotoxicity against human HEK293 cells assessed as cell growth inhibition incubated for 4 days by MTT assay Cytotoxicity against human HEK293 cells assessed as cell growth inhibition incubated for 4 days by MTT assay	[PMID: 37506545]
HeLa	IC₅₀	4 pM Compound: Staurosporine	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21388191]
HeLa	IC₅₀	4 pM Compound: Staurosporine	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21488655]
HeLa	EC₅₀	29.12 μg/mL Compound: Staurosporine	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21889345]
HeLa	IC₅₀	0.175 μM Compound: Staurosporine	Cytotoxicity against human HeLa cells after 72 hrs by Calcein AM assay Cytotoxicity against human HeLa cells after 72 hrs by Calcein AM assay	[PMID: 22921081]
HeLa	IC₅₀	9.12 μM Compound: Staurosporine	Antiproliferative activity against human HeLa cells after 48 hrs by MTT method Antiproliferative activity against human HeLa cells after 48 hrs by MTT method	[PMID: 23018096]
HeLa	IC₅₀	2.72 μM Compound: Staurosporine	Antiproliferative activity against human HeLa cells after 24 to 48 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells after 24 to 48 hrs by CCK-8 assay	[PMID: 24792811]
HeLa	IC₅₀	0.025 μM Compound: staurosporine	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25825934]
HeLa	IC₅₀	0.025 μM Compound: Staurosporine	Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay	10.1039/C2MD20098H
HeLa	IC₅₀	0.025 μmol Compound: Staurosporine	Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay	10.1039/C2MD20098H
HeLa S3	IC₅₀	4 pM Compound: Staurosporine	Cytotoxicity against human HeLa S3 cells measured after 72 hrs Cytotoxicity against human HeLa S3 cells measured after 72 hrs	[PMID: 32688198]
HepG2	EC₅₀	21.74 μg/mL Compound: Staurosporine	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 21889345]
HepG2	IC₅₀	4.14 μM Compound: Staurosporine	Inhibition of telomerase in human HepG2 cells after 24 hrs by TRAP-PCR-ELISA assay Inhibition of telomerase in human HepG2 cells after 24 hrs by TRAP-PCR-ELISA assay	[PMID: 23018096]
HepG2	IC₅₀	6.73 μM Compound: Staurosporine	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT method Antiproliferative activity against human HepG2 cells after 48 hrs by MTT method	[PMID: 23018096]
HepG2	IC₅₀	8.3 μM Compound: Staurosporine	Inhibition of telomerase in human HepG2 cells after 48 hrs by TRAP-PCR-ELISA Inhibition of telomerase in human HepG2 cells after 48 hrs by TRAP-PCR-ELISA	[PMID: 23279864]
HepG2	EC₅₀	<2 μM Compound: Staurosporine	Cytotoxicity against human HepG2 cells Cytotoxicity against human HepG2 cells	[PMID: 25316317]
HepG2	IC₅₀	0.018 μM Compound: Staurosporine	Cytotoxicity against human HepG2 cells at 100 uM after 3 days by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human HepG2 cells at 100 uM after 3 days by CellTiter-Glo luminescent cell viability assay	[PMID: 28993106]
HepG2	IC₅₀	5.07 μM Compound: Staurosporine	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 36848846]
HepG2	IC₅₀	9.04 μM Compound: Staurosporine	Antiproliferative activity against Homo sapiens (human) HepG2 cells assessed as growth inhibition after 48 hr by MTT assay Antiproliferative activity against Homo sapiens (human) HepG2 cells assessed as growth inhibition after 48 hr by MTT assay	10.1007/s00044-012-0306-5
HL-60	IC₅₀	9.24 μM Compound: Staurosporine	Cytostatic activity against human HL60 cells Cytostatic activity against human HL60 cells	[PMID: 30738653]
HL-60	IC₅₀	0.019 μM Compound: Staurosporine	Antiproliferative activity against human HL60 cells Antiproliferative activity against human HL60 cells	[PMID: 31005446]
HL-60	IC₅₀	0.04 μM Compound: STS	Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
HL-60	IC₅₀	0.0076 μM Compound: Staurosporine	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
HL-60	IC₅₀	0.041 μM Compound: Staurosporine	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]
HMLE	IC₅₀	4.9 nM Compound: 1	Cytotoxicity against human HMLE cells assessed as reduction in cell metabolic activity after 72 hrs by MTS assay Cytotoxicity against human HMLE cells assessed as reduction in cell metabolic activity after 72 hrs by MTS assay	[PMID: 33335665]
HOP-92	GI₅₀	9.99 μM Compound: Staurosporine	Cytotoxicity against human HOP-92 cells assessed as cell growth inhibition incubated for 4 days by MTT assay Cytotoxicity against human HOP-92 cells assessed as cell growth inhibition incubated for 4 days by MTT assay	[PMID: 37506545]
HT-29	GI₅₀	10.9 nM Compound: staurosporine	Cytotoxicity against human HT29 cells after 72 hrs by sulforhodamine B method Cytotoxicity against human HT29 cells after 72 hrs by sulforhodamine B method	[PMID: 18484775]
HT-29	ED₅₀	2.6 nM Compound: staurosporine	Induction of apoptosis in human HT-29 cells assessed as change in mitochondrial transmembrane potential after 2 hrs by JC1 staining based fluorescence assay Induction of apoptosis in human HT-29 cells assessed as change in mitochondrial transmembrane potential after 2 hrs by JC1 staining based fluorescence assay	[PMID: 19422206]
HT-29	IC₅₀	2 nM Compound: Staurosporine	Effect on mitochondrial membrane potential in human HT-29 cells after 2 hrs using JC-1 staining by fluorescence assay Effect on mitochondrial membrane potential in human HT-29 cells after 2 hrs using JC-1 staining by fluorescence assay	[PMID: 21428375]
HT-29	IC₅₀	2.5 nM Compound: Staurosporine	Inhibition of mitochondrial membrane potential in human HT-29 cells using JC1 dye staining by fluorescence plate reader assay Inhibition of mitochondrial membrane potential in human HT-29 cells using JC1 dye staining by fluorescence plate reader assay	[PMID: 21513293]
HT-29	GI₅₀	3.6 μM Compound: Staurosporine	Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay	[PMID: 21513294]
HT-29	ED₅₀	>20 μM Compound: Staurosporine	Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay	[PMID: 21973101]
HT-29	ED₅₀	0.0026 μM Compound: Staurosporine	Induction of apoptosis in human HT-29 cells assessed reduction of mitochondrial membrane potential after 2 hrs by using JC1 staining by fluorescence cell-based assay Induction of apoptosis in human HT-29 cells assessed reduction of mitochondrial membrane potential after 2 hrs by using JC1 staining by fluorescence cell-based assay	[PMID: 21973101]
HT-29	IC₅₀	0.2 μM Compound: STP	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 24361521]
HT-29	EC₅₀	0.15 μM Compound: STS	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 29197730]
HT-29	IC₅₀	20 nM Compound: Staurosporine	Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay	[PMID: 30057155]
HT-29	EC₅₀	0.2 μM Compound: STS	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
HT-29	IC₅₀	0.01 μM Compound: STS	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth	[PMID: 32201021]
HT-29	IC₅₀	0.2 μM Compound: ST	Cytotoxicity against human HT29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human HT29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32422522]
HT-29	EC₅₀	0.2 μM Compound: Staurosporine	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 33049606]
Huh-7	IC₅₀	0.23 μM Compound: Staurosporine	Cytotoxicity against human HuH7 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay Cytotoxicity against human HuH7 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay	[PMID: 24328283]
HUVEC	IC₅₀	0.004 μM Compound: Staurosporine	Antiproliferative activity against human umbilical vein endothelial cells (HUVECs) using MTT assay Antiproliferative activity against human umbilical vein endothelial cells (HUVECs) using MTT assay	[PMID: 11591505]
HUVEC	IC₅₀	0.004 μM Compound: Staurosporine	Antiproliferative activity against human HUVEC after 48 to 72 hrs by MTT assay Antiproliferative activity against human HUVEC after 48 to 72 hrs by MTT assay	[PMID: 22182929]
HUVEC	IC₅₀	0.5 μM Compound: STS	Cytotoxicity against HUVEC cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against HUVEC cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 34671737]
Jurkat	IC₅₀	311 nM Compound: staurosporine	Antiproliferative activity against JAK3 expressing human resting Jurkat cells Antiproliferative activity against JAK3 expressing human resting Jurkat cells	[PMID: 19427203]
Jurkat	IC₅₀	71 nM Compound: staurosporine	Antiproliferative activity against JAK3 expressing IL2-stimulated human Jurkat cells Antiproliferative activity against JAK3 expressing IL2-stimulated human Jurkat cells	[PMID: 19427203]
Jurkat	IC₅₀	0.14 μM Compound: Staurosporine	Cytotoxicity against human Jurkat cells after 72 hrs by CellTitre-Glo luminescent cell viability assay Cytotoxicity against human Jurkat cells after 72 hrs by CellTitre-Glo luminescent cell viability assay	[PMID: 24328283]
Jurkat	IC₅₀	0.0393 μM Compound: Staurosporine	Cytotoxicity against human Jurkat cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Cytotoxicity against human Jurkat cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]
Jurkat	IC₅₀	3.2 μM Compound: Staurosporine	Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay	[PMID: 35196017]
Jurkat	IC₅₀	0.003 μM Compound: Staurosporine	Inhibitory activity against protein kinase C from Jurkat cells. Inhibitory activity against protein kinase C from Jurkat cells.	10.1016/S0960-894X(01)80408-X
K562	IC₅₀	153 μM Compound: STSP	Antitumor activity against human K562 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Antitumor activity against human K562 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 26022079]
K562	IC₅₀	1.7 μM Compound: Staurosporine	Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 30106291]
K562	IC₅₀	23.1 μM Compound: Staurosporine	Cytostatic activity against human K562 cells Cytostatic activity against human K562 cells	[PMID: 30738653]
K562	IC₅₀	0.083 μM Compound: Staurosporine	Antiproliferative activity against human K562 cells Antiproliferative activity against human K562 cells	[PMID: 31005446]
K562	IC₅₀	0.04 μM Compound: STS	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
K562	IC₅₀	0.0768 μM Compound: Staurosporine	Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
K562	IC₅₀	>0.1 μM Compound: Staurosporine	Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]
KB	ED₅₀	0.0024 μg/mL Compound: 1	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 3204380]
KB 3-1	IC₅₀	<0.2 μM Compound: Staurosporine	Antiproliferative activity against human KB-3-1 cells after 5 days by WST-1 assay Antiproliferative activity against human KB-3-1 cells after 5 days by WST-1 assay	[PMID: 28956915]
KOPN-8	EC₅₀	0.71 μM Compound: STS	Antiproliferative activity against human KOPN8 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human KOPN8 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30840453]
L02	IC₅₀	9.5 μM Compound: Staurosporine	Cytotoxicity against human LO2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 30106291]
L929	IC₅₀	<0.2 μM Compound: Staurosporine	Antiproliferative activity against mouse L929 cells after 5 days by WST-1 assay Antiproliferative activity against mouse L929 cells after 5 days by WST-1 assay	[PMID: 28956915]
Leukemia cell	EC₅₀	0.35 μM Compound: STS	Antiproliferative activity against mouse leukemia cells overexpressing BCR/ABL after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against mouse leukemia cells overexpressing BCR/ABL after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30840453]
LN-229	IC₅₀	0.003 μM Compound: STS	Antiproliferative activity against human LN229 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human LN229 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
LN-229	IC₅₀	0.0097 μM Compound: Staurosporine	Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	[PMID: 34352711]
LoVo	IC₅₀	0.001 μM Compound: Staurosporine	Antiproliferative activity against human colon cancer cell line (LoVo cells) using MTT assay Antiproliferative activity against human colon cancer cell line (LoVo cells) using MTT assay	[PMID: 11591505]
LoVo	IC₅₀	0.001 μM Compound: Staurosporine	Antiproliferative activity against human LoVo cells after 48 to 72 hrs by MTT assay Antiproliferative activity against human LoVo cells after 48 to 72 hrs by MTT assay	[PMID: 22182929]
LOX IMVI	IC₅₀	7.15 μM Compound: Staurosporine	Cytotoxicity against human LOX IMVI cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human LOX IMVI cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33601311]
MCF-10A	IC₅₀	18.01 μM Compound: Staurosporine	Cytotoxicity against human MCF-10A cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human MCF-10A cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 38107182]
MCF7	IC₅₀	2 μM Compound: Staurosporine	Inhibition of PKA in human MCF7 cells by array-based fluorescence assay Inhibition of PKA in human MCF7 cells by array-based fluorescence assay	[PMID: 18656369]
MCF7	IC₅₀	50 nM Compound: Staurosporine	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21388191]
MCF7	IC₅₀	50 nM Compound: Staurosporine	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21488655]
MCF7	GI₅₀	11 μM Compound: Staurosporine	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 21513294]
MCF7	IC₅₀	3.07 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 22503364]
MCF7	IC₅₀	180 nM Compound: Staurosporine	Cytotoxicity against human MCF7 cells after 24 hrs using Annexin VeFITC/propidium iodide staining by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs using Annexin VeFITC/propidium iodide staining by MTT assay	[PMID: 22541051]
MCF7	IC₅₀	0.064 μM Compound: Staurosporine	Cytotoxicity against human MCF7 cells after 72 hrs by Calcein AM assay Cytotoxicity against human MCF7 cells after 72 hrs by Calcein AM assay	[PMID: 22921081]
MCF7	IC₅₀	0.52 μM Compound: Staurosporine	Cytotoxicity against human MCF7 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay Cytotoxicity against human MCF7 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay	[PMID: 24328283]
MCF7	IC₅₀	0.4 μM Compound: STP	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 24361521]
MCF7	IC₅₀	1.8 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells after 5 days by WST-1 assay Antiproliferative activity against human MCF7 cells after 5 days by WST-1 assay	[PMID: 28956915]
MCF7	EC₅₀	0.1 μM Compound: STS	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 29197730]
MCF7	EC₅₀	0.1 μM Compound: STS	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
MCF7	IC₅₀	3.39 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells measured after 48 hrs under normoxic condition by MTT assay Antiproliferative activity against human MCF7 cells measured after 48 hrs under normoxic condition by MTT assay	[PMID: 31972394]
MCF7	IC₅₀	9.2 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells measured after 48 hrs under CoCl2-induced hypoxic condition by MTT assay Antiproliferative activity against human MCF7 cells measured after 48 hrs under CoCl2-induced hypoxic condition by MTT assay	[PMID: 31972394]
MCF7	IC₅₀	0.33 μM Compound: Staurosporine	Inhibition of VEGFR2 in human MCF7 cells by horseradish peroxidase-coupled TMB substrate based ELISA Inhibition of VEGFR2 in human MCF7 cells by horseradish peroxidase-coupled TMB substrate based ELISA	[PMID: 31992477]
MCF7	IC₅₀	8.81 μM Compound: Staurosporine	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 3 days by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 3 days by MTT assay	[PMID: 31992477]
MCF7	IC₅₀	0.02 μM Compound: STS	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth	[PMID: 32201021]
MCF7	IC₅₀	0.1 μM Compound: ST	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32422522]
MCF7	IC₅₀	3.67 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs under normaxic condition by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs under normaxic condition by MTT assay	[PMID: 32877804]
MCF7	IC₅₀	7.33 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs under chemically-induced hypoxic condition by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs under chemically-induced hypoxic condition by MTT assay	[PMID: 32877804]
MCF7	EC₅₀	0.1 μM Compound: Staurosporine	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 33049606]
MCF7	IC₅₀	3.67 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells incubated for 2 days by MTT assay Antiproliferative activity against human MCF7 cells incubated for 2 days by MTT assay	[PMID: 33667848]
MCF7	IC₅₀	4.1 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34482273]
MCF7	IC₅₀	6.08 μM Compound: Staurosporine	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 3 days by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 3 days by MTT assay	[PMID: 34743062]
MCF7	IC₅₀	4.1 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay	[PMID: 34871842]
MCF7	IC₅₀	6.3 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay	[PMID: 35196017]
MCF7	IC₅₀	7.25 μM Compound: Staurosporine	Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35694689]
MCF7	IC₅₀	6.76 μM Compound: Staurosporine	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 36848846]
MCF7	IC₅₀	3.18 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 37501287]
MCF7	IC₅₀	3.144 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38283222]
MCF7	IC₅₀	16.06 μM Compound: Staurosporine	Antiproliferative activity against Homo sapiens (human) MCF7 cells assessed as growth inhibition after 48 hr by MTT assay Antiproliferative activity against Homo sapiens (human) MCF7 cells assessed as growth inhibition after 48 hr by MTT assay	10.1007/s00044-012-0306-5
MCF7	IC₅₀	0.013 μM Compound: Staurosporine	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay	10.1039/C2MD20098H
MCF7	IC₅₀	0.013 μmol Compound: Staurosporine	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay	10.1039/C2MD20098H
MDA-MB-231	GI₅₀	7.1 nM Compound: staurosporine	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B method Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B method	[PMID: 18484775]
MDA-MB-231	IC₅₀	0.24 μM Compound: Staurosporine	Cytotoxic activity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay Cytotoxic activity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay	[PMID: 28705432]
MDA-MB-231	IC₅₀	4.25 μM Compound: Staurosporine	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by SRB assay	[PMID: 32044580]
MDA-MB-231	IC₅₀	4.31 μM Compound: Staurosporine	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs under normaxic condition by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs under normaxic condition by MTT assay	[PMID: 32877804]
MDA-MB-231	IC₅₀	6.75 μM Compound: Staurosporine	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs under chemically-induced hypoxic condition by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs under chemically-induced hypoxic condition by MTT assay	[PMID: 32877804]
MDA-MB-231	IC₅₀	0.01 μM Compound: Staurosporin	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs	[PMID: 33139111]
MDA-MB-231	IC₅₀	2.5 nM Compound: 1	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell metabolic activity after 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell metabolic activity after 72 hrs by MTS assay	[PMID: 33335665]
MDA-MB-231	IC₅₀	6.75 μM Compound: Staurosporine	Antiproliferative activity against human MDA-MB-231 cells incubated for 2 days by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 2 days by MTT assay	[PMID: 33667848]
MDA-MB-231	IC₅₀	0.85 nM Compound: Staurosporine	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 34656041]
MDA-MB-231	IC₅₀	4.385 μM Compound: Staurosporine	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38283222]
MDA-MB-453	IC₅₀	0.02351 μM Compound: Staurosporine	Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 34656041]
MDA-MB-468	IC₅₀	0.15 μM Compound: Staurosporine	Cytotoxic activity against human MDA-MB-468 cells incubated for 24 hrs by MTT assay Cytotoxic activity against human MDA-MB-468 cells incubated for 24 hrs by MTT assay	[PMID: 28705432]
MDA-MB-468	IC₅₀	4.37 μM Compound: Staurosporine	Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs under normoxic condition by MTT assay Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs under normoxic condition by MTT assay	[PMID: 31972394]
MDA-MB-468	IC₅₀	6.46 μM Compound: Staurosporine	Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs under CoCl2-induced hypoxic condition by MTT assay Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs under CoCl2-induced hypoxic condition by MTT assay	[PMID: 31972394]
MDA-MB-468	IC₅₀	0.005 μM Compound: STS	Antiproliferative activity against human MDA-MB-468 cells assessed inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-468 cells assessed inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 37037136]
MDA-MB-468	IC₅₀	6.358 μM Compound: Staurosporine	Cytotoxicity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 38107182]
MGC-803	IC₅₀	8.97 μM Compound: Staurosporine	Inhibition of telomerase in human MGC-803 cells after 24 hrs by TRAP-PCR-ELISA assay Inhibition of telomerase in human MGC-803 cells after 24 hrs by TRAP-PCR-ELISA assay	[PMID: 26900656]
MIA PaCa-2	IC₅₀	370 nM Compound: Staurosporine	Antiproliferative activity against MiaPaCa-2 cells by MTT assay Antiproliferative activity against MiaPaCa-2 cells by MTT assay	[PMID: 16403626]
MIA PaCa-2	IC₅₀	370 nM Compound: Staurosporine	Antiproliferative activity against human MiaPaCa-2 cells Antiproliferative activity against human MiaPaCa-2 cells	[PMID: 16413780]
MM1.S	IC₅₀	0.0442 μM Compound: Staurosporine	Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
MRC5	GI₅₀	27.27 μM Compound: Staurosporine	Cytotoxicity against human MRC5 cells assessed as cell growth inhibition incubated for 4 days by MTT assay Cytotoxicity against human MRC5 cells assessed as cell growth inhibition incubated for 4 days by MTT assay	[PMID: 37506545]
MV4-11	IC₅₀	0.05 μM Compound: Staurosporine	Cytotoxicity against human MV4-11cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Cytotoxicity against human MV4-11cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]
N2a	IC₅₀	0.0113 μM Compound: Staurosporine	Cytotoxicity against mouse Neuro2a cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against mouse Neuro2a cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 28152427]
NALM-6	EC₅₀	1.4 μM Compound: STS	Antiproliferative activity against human NALM6 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human NALM6 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30840453]
NCI-H1975	IC₅₀	0.005 μM Compound: Staurosporine	Anticancer activity against TKI resistant human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as inhibition of cell growth Anticancer activity against TKI resistant human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as inhibition of cell growth	[PMID: 38199330]
NCI-H460	GI₅₀	3.6 μM Compound: Staurosporine	Cytotoxicity against human H460 cells after 48 hrs by SRB assay Cytotoxicity against human H460 cells after 48 hrs by SRB assay	[PMID: 21513294]
NCI-H460	IC₅₀	11.5 μM Compound: Staurosporine	Cytostatic activity against human NCI-H460 cells Cytostatic activity against human NCI-H460 cells	[PMID: 30738653]
NCI-H460	IC₅₀	0.024 μM Compound: Staurosporine	Antiproliferative activity against human NCI-H460 cells Antiproliferative activity against human NCI-H460 cells	[PMID: 31005446]
NCI-H460	IC₅₀	0.06 μM Compound: STS	Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
NCI-H460	IC₅₀	0.0597 μM Compound: Staurosporine	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
NCI-H460	IC₅₀	>0.1 μM Compound: Staurosporine	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	[PMID: 34352711]
NIH3T3	IC₅₀	140.12 μM Compound: Staurosporine	Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay	[PMID: 24286761]
NIH3T3	IC₅₀	0.2 μM Compound: STP	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 24361521]
NIH3T3	EC₅₀	0.008 μM Compound: STS	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 29197730]
NIH3T3	EC₅₀	0.008 μM Compound: STS	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
NIH3T3	IC₅₀	0.008 μM Compound: ST	Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32422522]
NIH3T3	EC₅₀	0.008 μM Compound: Staurosporine	Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 33049606]
P19	IC₅₀	>10 μM Compound: Staurosporine	Inhibition of Casein kinase 2 of P19 cells Inhibition of Casein kinase 2 of P19 cells	[PMID: 15771419]
P19	IC₅₀	>10 μM Compound: Staurosporine	Inhibition of Epidermal growth factor receptor in P19 cells Inhibition of Epidermal growth factor receptor in P19 cells	[PMID: 15771419]
P19	IC₅₀	>10 μM Compound: Staurosporine	Inhibition of Mitogen-activated protein kinase/extracellular signal-regulated kinase 2 in P19 cells Inhibition of Mitogen-activated protein kinase/extracellular signal-regulated kinase 2 in P19 cells	[PMID: 15771419]
P19	IC₅₀	0.002 μM Compound: Staurosporine	Inhibition of Platelet-derived growth factor receptor in P19 cells Inhibition of Platelet-derived growth factor receptor in P19 cells	[PMID: 15771419]
P19	IC₅₀	0.004 μM Compound: Staurosporine	Inhibition of Protein Kinase A in P19 cells Inhibition of Protein Kinase A in P19 cells	[PMID: 15771419]
P19	IC₅₀	0.006 μM Compound: Staurosporine	Inhibition of Calcium/calmodulin-dependent protein kinase type II in P19 cells Inhibition of Calcium/calmodulin-dependent protein kinase type II in P19 cells	[PMID: 15771419]
P19	IC₅₀	0.008 μM Compound: Staurosporine	Inhibition of Cyclin-dependent kinase 1 in P19 cells Inhibition of Cyclin-dependent kinase 1 in P19 cells	[PMID: 15771419]
P19	IC₅₀	0.014 μM Compound: Staurosporine	Inhibition of Vascular endothelial growth factor receptor in P19 cells Inhibition of Vascular endothelial growth factor receptor in P19 cells	[PMID: 15771419]
P19	IC₅₀	0.2 μM Compound: Staurosporine	Inhibition of Insulin receptor kinase in P19 cells Inhibition of Insulin receptor kinase in P19 cells	[PMID: 15771419]
P19	IC₅₀	1.4 μM Compound: Staurosporine	Inhibition of Casein kinase 1 in P19 cells Inhibition of Casein kinase 1 in P19 cells	[PMID: 15771419]
P388	ED₅₀	<0.08 μg/mL Compound: 1	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 3204380]
PANC-1	IC₅₀	0.02 μM Compound: STS	Antiproliferative activity against human PANC1 cells assessed as inhibition of cell growth Antiproliferative activity against human PANC1 cells assessed as inhibition of cell growth	[PMID: 32201021]
PBMC	IC₅₀	0.016 μM Compound: 1	Suppression of IL2 production in human PBMC after 24 hrs by ELISA Suppression of IL2 production in human PBMC after 24 hrs by ELISA	[PMID: 18585046]
PBMC	IC₅₀	0.016 μM Compound: staurosporine	Inhibition of IL2 production in PHA-stimulated human PBMC after 24 hrs by ELISA Inhibition of IL2 production in PHA-stimulated human PBMC after 24 hrs by ELISA	[PMID: 18823784]
PBMC	IC₅₀	0.0002 μM Compound: Staurosporine	Cytotoxicity against human PBMC cells assessed as inhibition of cell proliferation measured after 72 hrs by radioactive cell proliferation assay Cytotoxicity against human PBMC cells assessed as inhibition of cell proliferation measured after 72 hrs by radioactive cell proliferation assay	[PMID: 33248847]
PBMC	IC₅₀	0.2 nM Compound: Staurosporine	Cytotoxicity against human PBMC cells assessed as inhibition of cell proliferation measured after 72 hrs by radioactive cell proliferation assay Cytotoxicity against human PBMC cells assessed as inhibition of cell proliferation measured after 72 hrs by radioactive cell proliferation assay	[PMID: 33248847]
PC-3	IC₅₀	0.031 μM Compound: staurosporine	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 25825934]
PC-3	IC₅₀	0.017 μM Compound: Staurosporine	Cytotoxicity against human PC3 cells by sulforhodamine B assay Cytotoxicity against human PC3 cells by sulforhodamine B assay	[PMID: 29389122]
PC-3	IC₅₀	0.039 μM Compound: STU	Cytotoxicity against human PC3 cells after 72 hrs by SRB assay Cytotoxicity against human PC3 cells after 72 hrs by SRB assay	[PMID: 29558119]
PC-3	IC₅₀	4.91 μM Compound: Staurosporine	Antiproliferative activity against human PC3 cells measured after 72 hrs under normoxic condition by MTT assay Antiproliferative activity against human PC3 cells measured after 72 hrs under normoxic condition by MTT assay	[PMID: 31794211]
PC-3	IC₅₀	5.92 μM Compound: Staurosporine	Antiproliferative activity against human PC3 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay Antiproliferative activity against human PC3 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay	[PMID: 31794211]
PC-3	IC₅₀	0.36 μM Compound: Staurosporine	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 36848846]
Platelet	IC₅₀	48 nM Compound: Staurosporine	Inhibition of alpha-thrombin induced human Platelet aggregation pre-incubated for 1 min followed by alpha-thrombin stimulation and measured after 30 sec by aggregometer assay Inhibition of alpha-thrombin induced human Platelet aggregation pre-incubated for 1 min followed by alpha-thrombin stimulation and measured after 30 sec by aggregometer assay	[PMID: 1874734]
Platelet	IC₅₀	76 nM Compound: Staurosporine	Inhibition of collagen induced human Platelet aggregation pre-incubated for 1 min followed by collagen stimulation and measured after 30 sec by aggregometer assay Inhibition of collagen induced human Platelet aggregation pre-incubated for 1 min followed by collagen stimulation and measured after 30 sec by aggregometer assay	[PMID: 1874734]
Raji	EC₅₀	<2 μM Compound: Staurosporine	Cytotoxicity against human Raji cells Cytotoxicity against human Raji cells	[PMID: 25316317]
RBL-2H3	IC₅₀	0.2 μM Compound: Staurosporine	Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced IL-4 level preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by ELISA Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced IL-4 level preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by ELISA	[PMID: 30711393]
RBL-2H3	IC₅₀	0.3 μM Compound: Staurosporine	Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced beta-hexosaminidase release preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by p-nitrophenyl-2-acetamide-2-deoxy-be Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced beta-hexosaminidase release preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by p-nitrophenyl-2-acetamide-2-deoxy-be	[PMID: 30711393]
RBL-2H3	IC₅₀	0.3 μM Compound: Staurosporine	Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced TNF-alpha level preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by ELISA Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced TNF-alpha level preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by ELISA	[PMID: 30711393]
RBL-2H3	IC₅₀	0.7 μM Compound: Staurosporine	Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced IL-4 level preincubated for 15 mins followed by calcium ionophore stimulation and measured after 3 hrs by ELISA Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced IL-4 level preincubated for 15 mins followed by calcium ionophore stimulation and measured after 3 hrs by ELISA	[PMID: 30711393]
RBL-2H3	IC₅₀	1 μM Compound: Staurosporine	Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced beta-hexosaminidase release preincubated for 15 mins followed by calcium ionophore-stimulation and measured after 3 hrs by p-nitrophenyl-2-acetamide-2-deoxy-beta Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced beta-hexosaminidase release preincubated for 15 mins followed by calcium ionophore-stimulation and measured after 3 hrs by p-nitrophenyl-2-acetamide-2-deoxy-beta	[PMID: 30711393]
RBL-2H3	IC₅₀	1 μM Compound: Staurosporine	Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced TNF-alpha level preincubated for 15 mins followed by calcium ionophore stimulation and measured after 3 hrs by ELISA Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced TNF-alpha level preincubated for 15 mins followed by calcium ionophore stimulation and measured after 3 hrs by ELISA	[PMID: 30711393]
RBL-2H3	IC₅₀	0.3 μM Compound: Staurosporine	Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of mouse anti-DNP IgE-stimulated beta-hexosaminidase release preincubated for 15 mins followed by mouse anti-DNP IgE stimulation and measured after 3 hrs by 4-nitropheny1-2-acetamide-2-deoxy-bet Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of mouse anti-DNP IgE-stimulated beta-hexosaminidase release preincubated for 15 mins followed by mouse anti-DNP IgE stimulation and measured after 3 hrs by 4-nitropheny1-2-acetamide-2-deoxy-bet	[PMID: 31879206]
RBL-2H3	IC₅₀	0.5 μM Compound: Staurosporine	Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of anti-DNP IgE-stimulated TNFalpha release preincubated for 15 mins followed by mouse anti-DNP IgE stimulation and measured after 3 hrs by ELISA Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of anti-DNP IgE-stimulated TNFalpha release preincubated for 15 mins followed by mouse anti-DNP IgE stimulation and measured after 3 hrs by ELISA	[PMID: 31879206]
RBL-2H3	IC₅₀	0.8 μM Compound: Staurosporine	Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of ionomycin-stimulated beta-hexosaminidase release preincubated for 15 mins followed by ionomycin stimulation and measured after 3 hrs by 4-nitropheny1-2-acetamide-2-deoxy-beta-glucopyranoside Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of ionomycin-stimulated beta-hexosaminidase release preincubated for 15 mins followed by ionomycin stimulation and measured after 3 hrs by 4-nitropheny1-2-acetamide-2-deoxy-beta-glucopyranoside	[PMID: 31879206]
RBL-2H3	IC₅₀	1 μM Compound: Staurosporine	Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of ionomycin-stimulated TNFalpha release preincubated for 15 mins followed by ionomycin stimulation and measured after 3 hrs by ELISA Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of ionomycin-stimulated TNFalpha release preincubated for 15 mins followed by ionomycin stimulation and measured after 3 hrs by ELISA	[PMID: 31879206]
Rec1	IC₅₀	0.0255 μM Compound: Staurosporine	Cytotoxicity against human REC1 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Cytotoxicity against human REC1 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]
RXF 393	GI₅₀	0.95 μM Compound: Staurosporine	Cytotoxicity against human RXF 393 cells assessed as cell growth inhibition incubated for 4 days by MTT assay Cytotoxicity against human RXF 393 cells assessed as cell growth inhibition incubated for 4 days by MTT assay	[PMID: 37506545]
Sf21	IC₅₀	6 nM Compound: 2	Inhibition of JAK3 expressed in Sf21 cells Inhibition of JAK3 expressed in Sf21 cells	[PMID: 17088059]
Sf21	IC₅₀	6 nM Compound: staurosporine	Inhibition of JAK3 expressed in insect Sf21 cells assessed as inhibition of biotinylated substrate phosphorylation Inhibition of JAK3 expressed in insect Sf21 cells assessed as inhibition of biotinylated substrate phosphorylation	[PMID: 19427203]
Sf21	IC₅₀	0.027 μM Compound: staurosporine	Inhibition of human CHK2 kinase expressed in insect Sf21 cells using phospho-CREBtide as substrate at 30 uM Inhibition of human CHK2 kinase expressed in insect Sf21 cells using phospho-CREBtide as substrate at 30 uM	[PMID: 21334796]
Sf21	IC₅₀	0.039 μM Compound: staurosporine	Inhibition of human recombinant IKK-alpha expressed in insect Sf21 cells using phospho-Ulight-IkappaB-alpha as substrate at 30 uM Inhibition of human recombinant IKK-alpha expressed in insect Sf21 cells using phospho-Ulight-IkappaB-alpha as substrate at 30 uM	[PMID: 21334796]
Sf21	IC₅₀	0.49 μM Compound: staurosporine	Inhibition of human recombinant IKK-beta expressed in insect Sf21 cells using phospho-Ulight-IkappaB-alpha as substrate at 30 uM Inhibition of human recombinant IKK-beta expressed in insect Sf21 cells using phospho-Ulight-IkappaB-alpha as substrate at 30 uM	[PMID: 21334796]
Sf21	IC₅₀	1325 nM Compound: Staurosporine	Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 5 mins by time resolved-fluorescent assay Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 5 mins by time resolved-fluorescent assay	[PMID: 21441024]
Sf21	IC₅₀	1533 nM Compound: Staurosporine	Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 30 mins by time resolved-fluorescent assay Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 30 mins by time resolved-fluorescent assay	[PMID: 21441024]
Sf21	IC₅₀	1646 nM Compound: Staurosporine	Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 60 mins by time resolved-fluorescent assay Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 60 mins by time resolved-fluorescent assay	[PMID: 21441024]
Sf21	IC₅₀	1701 nM Compound: Staurosporine	Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 10 mins by time resolved-fluorescent assay Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 10 mins by time resolved-fluorescent assay	[PMID: 21441024]
Sf21	IC₅₀	0.002 μM Compound: Staurosporine	Inhibition of human recombinant JAK2 expressed in Sf21 cells assessed as reduction in Ulight-CAGAGAIETDKEYYTVKD phosphorylation pre-incubated before substrate addition and measured after 60 mins by LANCE detection method Inhibition of human recombinant JAK2 expressed in Sf21 cells assessed as reduction in Ulight-CAGAGAIETDKEYYTVKD phosphorylation pre-incubated before substrate addition and measured after 60 mins by LANCE detection method	[PMID: 27137359]
SF-268	GI₅₀	0.044 μM Compound: Staurosporine	Cytotoxicity against human SF268 cells after 48 hrs by SRB assay Cytotoxicity against human SF268 cells after 48 hrs by SRB assay	[PMID: 21513294]
Sf9	IC₅₀	0.005 μM Compound: Staurosporine	Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 1 umol/L ATP Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 1 umol/L ATP	[PMID: 17315853]
Sf9	IC₅₀	0.015 μM Compound: Staurosporine	Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 1 umol/L ATP Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 1 umol/L ATP	[PMID: 17315853]
Sf9	IC₅₀	0.036 μM Compound: Staurosporine	Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 10 umol/L ATP Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 10 umol/L ATP	[PMID: 17315853]
Sf9	IC₅₀	0.083 μM Compound: Staurosporine	Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 10 umol/L ATP Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 10 umol/L ATP	[PMID: 17315853]
Sf9	IC₅₀	0.27 μM Compound: Staurosporine	Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 100 umol/L ATP Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 100 umol/L ATP	[PMID: 17315853]
Sf9	IC₅₀	0.51 μM Compound: Staurosporine	Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 100 umol/L ATP Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 100 umol/L ATP	[PMID: 17315853]
Sf9	IC₅₀	0.003 μM Compound: staurosporine	Inhibition of human Syk expressed in Sf9 cells Inhibition of human Syk expressed in Sf9 cells	[PMID: 18823784]
Sf9	IC₅₀	0.053 μM Compound: staurosporine	Inhibition of human ZAP70 expressed in Sf9 cells Inhibition of human ZAP70 expressed in Sf9 cells	[PMID: 18823784]
Sf9	IC₅₀	2.3 μM Compound: staurosporine	Inhibition of human recombinant GST-fused NIK expressed in Sf9 cells after 60 mins by radiometric protein kinase assay Inhibition of human recombinant GST-fused NIK expressed in Sf9 cells after 60 mins by radiometric protein kinase assay	[PMID: 20580552]
Sf9	IC₅₀	>18.5 μM Compound: Staurosporine	Inhibition of human recombinant ALK5 expressed in insect Sf9 cells using casein as substrate by radioisotopic assay Inhibition of human recombinant ALK5 expressed in insect Sf9 cells using casein as substrate by radioisotopic assay	[PMID: 24786585]
Sf9	IC₅₀	1.2 nM Compound: Staurosporine	Inhibition of N-terminal GST tagged recombinant full-length human CHK1 expressed in baculovirus Sf9 insect cells after 10 mins by luminescent ADP-Glo assay Inhibition of N-terminal GST tagged recombinant full-length human CHK1 expressed in baculovirus Sf9 insect cells after 10 mins by luminescent ADP-Glo assay	[PMID: 27089211]
Sf9	IC₅₀	0.0039 μM Compound: Staurosporine	Inhibition of N-terminal His-tagged recombinant human AXL (473 to end amino acids) expressed by baculovirus in Sf9 cells using axltide substrate and ATP by ADP-Glo luminescence assay Inhibition of N-terminal His-tagged recombinant human AXL (473 to end amino acids) expressed by baculovirus in Sf9 cells using axltide substrate and ATP by ADP-Glo luminescence assay	[PMID: 30340900]
Sf9	IC₅₀	2.0 x 10^-8 M Compound: staurosporine	Inhibition of protein kinase C(1:1mixture of PKC alpha & beta) expressed in Sf9 insect cells Inhibition of protein kinase C(1:1mixture of PKC alpha & beta) expressed in Sf9 insect cells	[PMID: 9873605]
Splenocyte	IC₅₀	0.4 μM Compound: 1 (Staurosporine)	In vitro for inhibitory activity against tyrosine specific protein kinase from murine spleen cells (T-kinase) In vitro for inhibitory activity against tyrosine specific protein kinase from murine spleen cells (T-kinase)	10.1016/S0960-894X(01)80995-1
SR	GI₅₀	6.29 μM Compound: Staurosporine	Cytotoxicity against human SR cells assessed as cell growth inhibition incubated for 4 days by MTT assay Cytotoxicity against human SR cells assessed as cell growth inhibition incubated for 4 days by MTT assay	[PMID: 37506545]
SR	IC₅₀	2.62 μM Compound: Staurosporine	Antiproliferative activity against human SR cells assessed as inhibition of cell growth incubated for 2 to 4 hrs by MTT assay Antiproliferative activity against human SR cells assessed as inhibition of cell growth incubated for 2 to 4 hrs by MTT assay	[PMID: 38389871]
ST486	IC₅₀	0.007 μM Compound: Staurosporine	Antiproliferative activity against human ST486 cells after 48 to 72 hrs by MTT assay Antiproliferative activity against human ST486 cells after 48 to 72 hrs by MTT assay	[PMID: 22182929]
SUP-B15	EC₅₀	0.55 μM Compound: STS	Antiproliferative activity against human SUP-B15 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human SUP-B15 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30840453]
SW 1116	EC₅₀	24.92 μg/mL Compound: Staurosporine	Antiproliferative activity against human SW1116 cells after 48 hrs by MTT assay Antiproliferative activity against human SW1116 cells after 48 hrs by MTT assay	[PMID: 21889345]
SW 1116	IC₅₀	8.32 μM Compound: Staurosporine	Inhibition of telomerase in human SW1116 cells after 24 hrs by TRAP-PCR-ELISA assay Inhibition of telomerase in human SW1116 cells after 24 hrs by TRAP-PCR-ELISA assay	[PMID: 21962523]
SW 1116	IC₅₀	4.95 μM Compound: Staurosporine	Antiproliferative activity against human SW1116 cells after 48 hrs by MTT method Antiproliferative activity against human SW1116 cells after 48 hrs by MTT method	[PMID: 23018096]
SW 1116	IC₅₀	4.18 μM Compound: Staurosporine	Inhibition of telomerase in human SW1116 cells after 24 hrs by TRAP-PCR-ELISA assay Inhibition of telomerase in human SW1116 cells after 24 hrs by TRAP-PCR-ELISA assay	[PMID: 24286761]
SW-1736	EC₅₀	0.2 μM Compound: STS	Cytotoxicity against human SW1736 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human SW1736 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
SW480	IC₅₀	<0.1 μM Compound: Staurosporine	Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31740249]
T47D	IC₅₀	4.52 μM Compound: Staurosporine	Cytotoxicity against human T47D cells assessed as inhibition of cell proliferation measured after 72 hrs by SRB assay Cytotoxicity against human T47D cells assessed as inhibition of cell proliferation measured after 72 hrs by SRB assay	[PMID: 32044580]
T47D	IC₅₀	11.7 μM Compound: Staurosporine	Cytotoxicity against human T47D cells assessed as reduction in cell viability after 3 hrs by MTT assay Cytotoxicity against human T47D cells assessed as reduction in cell viability after 3 hrs by MTT assay	[PMID: 33962153]
T47D	IC₅₀	7.12 μM Compound: Staurosporine	Antiproliferative activity against human T47D cells incubated for 48 hrs by MTT assay Antiproliferative activity against human T47D cells incubated for 48 hrs by MTT assay	[PMID: 37501287]
T47D	IC₅₀	4.849 μM Compound: Staurosporine	Cytotoxicity against human T47D cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human T47D cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 38107182]
TERT-RPE1	IC₅₀	0.25 μM Compound: Staurosporine	Cytostatic activity against human hTERT-RPE1 cells Cytostatic activity against human hTERT-RPE1 cells	[PMID: 30738653]
TERT-RPE1	IC₅₀	0.0055 μM Compound: Staurosporine	Cytotoxicity against human TERT-RPE1 cells assessed as inhibition of cell proliferation measured after 72 hrs by real time imaging analysis Cytotoxicity against human TERT-RPE1 cells assessed as inhibition of cell proliferation measured after 72 hrs by real time imaging analysis	[PMID: 33248847]
U-87MG ATCC	IC₅₀	0.02 μM Compound: STS	Antiproliferative activity against human U87MG cells assessed as inhibition of cell growth Antiproliferative activity against human U87MG cells assessed as inhibition of cell growth	[PMID: 32201021]
U-937	IC₅₀	2 μM Compound: staurosporine	Cytotoxicity against human U937 cells Cytotoxicity against human U937 cells	[PMID: 17088067]
UoC-B1	EC₅₀	2 μM Compound: STS	Antiproliferative activity against human UOCB1 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human UOCB1 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30840453]
Vero	IC₅₀	0.0024 μM Compound: Staurosporine	Cytotoxicity against African green monkey Vero cells after 2 days by CellTiter-Glo luminescent cell viability assay Cytotoxicity against African green monkey Vero cells after 2 days by CellTiter-Glo luminescent cell viability assay	[PMID: 28993106]
Vero	IC₅₀	0.028 μM Compound: Staurosporine	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 30743094]
WI-38	IC₅₀	24.41 μM Compound: Staurosporine	Cytotoxicity against human WI-38 cells assessed as cell viability measured by MTT assay Cytotoxicity against human WI-38 cells assessed as cell viability measured by MTT assay	[PMID: 34246754]
Z-138	IC₅₀	21.5 μM Compound: Staurosporine	Cytostatic activity against human Z138 cells Cytostatic activity against human Z138 cells	[PMID: 30738653]
Z-138	IC₅₀	0.018 μM Compound: Staurosporine	Antiproliferative activity against human Z138 cells Antiproliferative activity against human Z138 cells	[PMID: 31005446]
Z-138	IC₅₀	0.02 μM Compound: STS	Antiproliferative activity against human Z138 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human Z138 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
Z-138	IC₅₀	0.0067 μM Compound: Staurosporine	Antiproliferative activity against human Z138 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human Z138 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
Z-138	IC₅₀	0.0418 μM Compound: Staurosporine	Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]

In Vitro

Staurosporine, widely used as a protein kinase C (PKC) inhibitor with a broad spectrum of activity, is an alkaloid which can be isolated from the culture broth of Streptomyces staurospores. MC3T3E-1 osteoblasts, expose to Staurosporine (100 nM) for 12 h, release an amount of LDH (12.4±3.1%) that is similar to that release by the control cells(10.0±2.4%), indicating the relative absence of lytic death, which occurs in necrosis. In addition, treatment with Staurosporine (100 nM) results in morphological changes, characteristic of apoptosis: a brightblue fluorescent condensed nuclei seen through a fluorescence microscope after Hoechst 33258-staining, and a reduction of cell volume^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The inhibitory effect of Staurosporine is statistically significant at around Wk 10 of tumor promotion. Although statistically significant inhibition is not obtained with 10 ng of Staurosporine in later weeks of the experiment, a decreasing tendency in the percentages of tumor bearing mice and in average numbers of tumors per mouse is apparent. Thus, Staurosporine slightly inhibits tumor promotion of Teleocidin, even at the dose at which Staurosporine itself induced tumors^[3]. Staurosponne (0.05 and 0.1 mg/kg intraperitoneal) attenuates the impaired perlormance of water maze and passive avoidance tasks, even though the drug administration began 2 weeks after the lesion. Moreover, Staurosporine (0.1 mg/kg) partially reversed the decrease of choline acetyltransferase activity in the fronto-parietal cortex induced by basal forebrain-lesion. These results suggest that Staurosporine attenuates impairment of learning through reversal of damage to cholinergic neurons induced by basal forebrain-lesion^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 62996-74-1
Appearance Solid
Molecular Weight 466.53
Formula C₂₈H₂₆N₄O₃
Color White to yellow
SMILES

O=C(NC1)C2=C1C3=C(C4=C2C5=C(C=CC=C5)N4[C@H]6C[C@@H](NC)[C@@H](OC)[C@]7(C)O6)N7C8=CC=CC=C83
Synonyms

Antibiotic AM-2282; STS; AM-2282
Structure Classification
- Alkaloids
- Indole Alkaloids
Initial Source
- Marine natural products
- Marine microorganism
- Microorganisms
Streptomyces staurosporeus
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (214)

All WB

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. [Abstract]

2020 Oct 9;5(1):235. PMID: 33037188

Staurosporine purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2020 Oct 9;5(1):235. [Abstract]

Mock-treated or SARS-CoV-2 (MOI = 0.1)-infected Calu-3 cells were collected at 48 h post infection and subjected to western blotting using the indicated antibodies. Cells treated with staurosporine (STS, 1 μM) for 24 h were used as a positive control. The arrow indicates the specific band of cleaved caspase-9.
Nature

Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors. [Abstract]

2025 Oct;646(8085):734-745. PMID: 40836083
Nature

Emergence of large-scale cell death through ferroptotic trigger waves. [Abstract]

2024 Jul;631(8021):654-662. PMID: 38987590
Nature

Nuclear sensing of breaks in mitochondrial DNA enhances immune surveillance. [Abstract]

2021 Mar;591(7850):477-481. PMID: 33627873
Cancer Cell

Radiotherapy promotes cuproptosis and synergizes with cuproptosis inducers to overcome tumor radioresistance. [Abstract]

2025 Apr 7:S1535-6108(25)00132-1. PMID: 40215978
Cancer Cell

Interleukin-1α release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity. [Abstract]

2024 Dec 9;42(12):2015-2031.e11. PMID: 39577420
Cell

TBK1 Suppresses RIPK1-Driven Apoptosis and Inflammation during Development and in Aging. [Abstract]

2018 Sep 6;174(6):1477-1491.e19. PMID: 30146158
Adv Mater

Ultrasound-Activated Sonophage Synergizes Sonodynamic Therapy and Saltoptosis for Solid Tumor Eradication. [Abstract]

2025 Oct 17:e08245. PMID: 41104711
Nat Biomed Eng

Profiling protein-protein interactions to predict the efficacy of B-cell-lymphoma-2-homology-3 mimetics for acute myeloid leukaemia. [Abstract]

2024 Nov;8(11):1379-1395. PMID: 39025942
Immunity

Acute suppression of mitochondrial ATP production prevents apoptosis and provides an essential signal for NLRP3 inflammasome activation. [Abstract]

2024 Nov 15:S1074-7613(24)00492-8. PMID: 39571574
Immunity

Oxidized DNA fragments exit mitochondria via mPTP- and VDAC-dependent channels to activate NLRP3 inflammasome and interferon signaling. [Abstract]

2022 Aug 9;55(8):1370-1385.e8. PMID: 35835107
Cell Res

Tom20 senses iron-activated ROS signaling to promote melanoma cell pyroptosis. [Abstract]

2018 Dec;28(12):1171-1185. PMID: 30287942
Cell Stem Cell

RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy. [Abstract]

2021 Dec 2;28(12):2076-2089.e7. PMID: 34525346
Cell Mol Immunol

The ORF3a protein of SARS-CoV-2 induces apoptosis in cells. [Abstract]

2020 Aug;17(8):881-883. PMID: 32555321

Staurosporine purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2020 Aug;17(8):881-883. [Abstract]

HEK293T cells were transfected with empty vector or FLAG-SARS-CoV-2 ORF3a. After 12 and 24 h, cells were subjected to western blotting analysis using the indicated antibodies. Cells treated with STS for 5 h were used as a positive control. STS, staurosporine.
Adv Funct Mater

2025 Aug 13.
Adv Funct Mater

2025 May 29.
Adv Funct Mater

2025 May 27.
Adv Funct Mater

2024 Sep 10.
Adv Funct Mater

2023 Apr 14.
Mol Cell

Splice-switching ASOs targeting the AURKA 5' UTR collapse an SRSF1-AURKA-MYC oncogenic circuit in pancreatic cancer. [Abstract]

2026 Jan 8;86(1):60-77.e7. PMID: 41475344
Cancer Res

Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. [Abstract]

2013 Apr 15;73(8):2574-86. PMID: 23436801

Staurosporine purchased from MedChemExpress. Usage Cited in: Cancer Res. 2013 Apr 15;73(8):2574-86. [Abstract]

Cells are treated with the indicated concentrations of AZD8055, Torin2 or staurosporin overnight and analyzed by western blot using antibodies specific for the indicated proteins.
ACS Nano

Microneedles Loaded with Nitric-Oxide Driven Nanomotors Improve Force-Induced Efferocytosis Impairment and Sterile Inflammation by Revitalizing Macrophage Energy Metabolism. [Abstract]

2025 Mar 11;19(9):9390-9411. PMID: 40025734
ACS Nano

Multifunctional Nanomedicine for Targeted Atherosclerosis Therapy: Activating Plaque Clearance Cascade and Suppressing Inflammation. [Abstract]

2025 Jan 28;19(3):3339-3361. PMID: 39812806
ACS Nano

Nanoparticle-Driven Controllable Mitochondrial Regulation through Lysosome-Mitochondria Interactome. [Abstract]

2022 Aug 23;16(8):12553-12568. PMID: 35876466
Nat Commun

Selective targeting of genome amplifications and repeat elements by CRISPR-Cas9 nickases to promote cancer cell death. [Abstract]

2025 Jun 2;16(1):5126. PMID: 40456709
Nat Commun

Coronavirus M protein promotes mitophagy over virophagy by recruiting PDPK1 to phosphorylate SQSTM1 at T138. [Abstract]

2024 Oct 16;15(1):8927. PMID: 39414765
J Am Chem Soc

ATP Site Ligands Determine the Assembly State of the Abelson Kinase Regulatory Core via the Activation Loop Conformation. [Abstract]

2018 Feb 7;140(5):1863-1869. PMID: 29319304
Cell Death Differ

Apoptotic caspase-7 activation inhibits non-canonical pyroptosis by GSDMB cleavage. [Abstract]

2023 Sep;30(9):2120-2134. PMID: 37591921
Acta Pharm Sin B

2025 Oct 24.
Autophagy

Kitasamycin overcomes ferroptosis and immunotherapy resistance by targeting the HUWE1-NCOA4-FTH1 axis. [Abstract]

2026 Feb 15:1-19. PMID: 41612599
Autophagy

Inhibition of PINK1 senses ROS signaling to facilitate neuroblastoma cell pyroptosis. [Abstract]

2025 Mar 31. PMID: 40160153
Autophagy

Atg14 protects the intestinal epithelium from TNF-triggered villus atrophy. [Abstract]

2019 Nov;15(11):1990-2001. PMID: 30894050
Adv Sci (Weinh)

Neoeriocitrin Targeting Beclin1 Deubiquitination and Autophagy in Osteogenic Differentiation of Human Dental Pulp Stem Cells. [Abstract]

2025 Aug 19:e04378. PMID: 40831238
Adv Sci (Weinh)

Apoptotic Bodies Derived from Fibroblast-Like Cells in Subcutaneous Connective Tissue Inhibit Ferroptosis in Ischaemic Flaps via the miR-339-5p/KEAP1/Nrf2 Axis. [Abstract]

2024 Jun;11(24):e2307238. PMID: 38639443
Adv Sci (Weinh)

Engineered Extracellular Vesicles Driven by Erythrocytes Ameliorate Bacterial Sepsis by Iron Recycling, Toxin Clearing and Inflammation Regulation. [Abstract]

2024 Apr;11(13):e2306884. PMID: 38247172
Adv Sci (Weinh)

Pyroptosis Remodeling Tumor Microenvironment to Enhance Pancreatic Cancer Immunotherapy Driven by Membrane Anchoring Photosensitizer. [Abstract]

2022 Oct;9(29):e2202914. PMID: 35981886
Theranostics

Ligand-directed oral lipidic nanoplatform enables sustained ferroptosis and immune reprogramming via multivalent transporter-mediated metronomic delivery. [Abstract]

2026 Jan 1;16(6):2952-2983. PMID: 41510171
Theranostics

Caspase-mediated AURKA cleavage at Asp132 is essential for paclitaxel to elicit cell apoptosis. [Abstract]

2024 Jun 17;14(10):3909-3926. PMID: 38994036
Theranostics

Palmitoylation of PKCδ by ZDHHC5 in hypothalamic microglia presents as a therapeutic target for fatty liver disease. [Abstract]

2024 Jan 1;14(3):988-1009. PMID: 38250049
Theranostics

Osteoclast-derived apoptotic bodies show extended biological effects of parental cell in promoting bone defect healing. [Abstract]

2020 May 22;10(15):6825-6838. PMID: 32550906
Chem Eng J

2025 Jun 1.
Chem Eng J

2025 Jun 1.
Chem Eng J

2024 Oct 1.
Biomaterials

A biomimetic nanoplatform boosting efferocytosis via dual-pathway regulation for atherosclerosis therapy and imaging. [Abstract]

2026 Aug:331:124090. PMID: 41762851
Biomaterials

Macrophage corpses for immunoregulation and targeted drug delivery in treatment of collagen-induced arthritis mice. [Abstract]

2025 Mar:314:122867. PMID: 39366181
Biomaterials

Automated discovery of nanomaterials via drug aggregation induced emission. [Abstract]

2022 Oct:289:121800. PMID: 36166893
J Nanobiotechnology

Engineered bone-targeting apoptotic vesicles as a minimally invasive nanotherapy for heterotopic ossification. [Abstract]

2025 May 14;23(1):348. PMID: 40369573
J Nanobiotechnology

Apoptotic vesicles from macrophages exacerbate periodontal bone resorption in periodontitis via delivering miR-143-3p targeting Igfbp5. [Abstract]

2024 Oct 26;22(1):658. PMID: 39456001
J Nanobiotechnology

Evaluating the pro-survival potential of apoptotic bodies derived from 2D- and 3D- cultured adipose stem cells in ischaemic flaps. [Abstract]

2024 Jun 14;22(1):333. PMID: 38877492
J Nanobiotechnology

Targeted delivery and ROS-responsive release of Resolvin D1 by platelet chimeric liposome ameliorates myocardial ischemia-reperfusion injury. [Abstract]

2022 Oct 20;20(1):454. PMID: 36266658
J Nanobiotechnology

Construction of gastric cancer patient-derived organoids and their utilization in a comparative study of clinically used paclitaxel nanoformulations. [Abstract]

2022 May 18;20(1):233. PMID: 35585597
Sci Adv

Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities. [Abstract]

2026 Jun 26;12(26):eadz3351. PMID: 42361179
Sci Adv

Direct recruitment of TONSOKU by the N-terminal tails of histone variants H2A.X and H2A.W coordinates DNA repair. [Abstract]

2025 Dec 19;11(51):eady2104. PMID: 41406205
Redox Biol

Fatty acids derived from apoptotic chondrocytes fuel macrophages FAO through MSR1 for facilitating BMSCs osteogenic differentiation. [Abstract]

2022 Apr 30;53:102326. PMID: 35525025
MedComm (2020)

Ubiquitin-specific protease 22 controls melanoma metastasis and vulnerability to ferroptosis through targeting SIRT1/PTEN/PI3K signaling. [Abstract]

2024 Aug 12;5(8):e684. PMID: 39135915
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
Cell Rep Med

Screening of patient-derived organoids identifies mitophagy as a cell-intrinsic vulnerability in colorectal cancer during statin treatment. [Abstract]

2025 Mar 19:102039. PMID: 40154491
Mater Today Bio

Porcine decellularized splenic matrix hydrogel-based vesicle sustained-release System: A dual-regulatory biomaterial for accelerated wound healing via angiogenesis and immune remodeling. [Abstract]

2025 Nov 26:35:102601. PMID: 41427061
Cancer Lett

The Zeb1/system Xc- axis safeguards iron-loaded cancer-associated fibroblasts against ferroptosis and promotes immunosuppression in prostate cancer. [Abstract]

2026 Feb 28:639:218243. PMID: 41485685
Int J Surg

Apoptotic extracellular vesicles from peripancreatic adipose-derived mesenchymal stem cells ameliorate severe acute pancreatitis through the transcription factor EB-mediated autophagy-lysosomal pathway: an experimental study. [Abstract]

2025 Dec 17. PMID: 41403290
Int J Biol Sci

Apoptin induces pyroptosis of colorectal cancer cells via the GSDME-dependent pathway. [Abstract]

2022 Jan 1;18(2):717-730. PMID: 35002520
J Colloid Interface Sci

Efficient biofunctionalization of MoS2 nanosheets with peptides as intracellular fluorescent biosensor for sensitive detection of caspase-3 activity. [Abstract]

2019 May 1:543:96-105. PMID: 30782521
Cell Death Dis

Identification of a small molecule targeting EPLIN as a novel strategy for the treatment of pediatric neuroblastoma and medulloblastoma. [Abstract]

2025 Jul 23;16(1):554. PMID: 40701975
Cell Death Dis

Apoptotic caspase inhibits innate immune signaling by cleaving NF-κBs in both Mammals and Flies. [Abstract]

2022 Aug 24;13(8):731. PMID: 36002459
Cell Death Dis

RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m6A-dependent manner. [Abstract]

2022 Jan 21;13(1):73. PMID: 35064112
Cell Death Dis

PURPL represses autophagic cell death to promote cutaneous melanoma by modulating ULK1 phosphorylation. [Abstract]

2021 Nov 10;12(11):1070. PMID: 34759263
J Cachexia Sarcopenia Muscle

C2C12-Derived ApoVs Promote Skeletal Muscle Development and Ameliorate Age-Related Muscle Loss Through Igf1r/PI3K/AKT/mTOR Pathway. [Abstract]

2025 Dec;16(6):e70159. PMID: 41344911
Small Methods

Plasma Membrane-Derived Biomimetic Apoptotic Nanovesicles Targeting Inflammation and Cartilage Degeneration for Osteoarthritis. [Abstract]

2024 Jul 22:e2400660. PMID: 39036830
Nano Res

2025 Oct.
J Pharm Anal

2026 Mar 11.
Cell Commun Signal

The aggressive colorectal cancer subtype marker HTR2B has a dual role depending on the tumor microenvironment. [Abstract]

2025 Oct 1;23(1):403. PMID: 41034989
Cell Commun Signal

Zinc-mediated activation of CREB pathway in proliferation of pulmonary artery smooth muscle cells in pulmonary hypertension. [Abstract]

2021 Oct 11;19(1):103. PMID: 34635097
ACS Appl Mater Interfaces

CpG-Conjugated Silver Nanoparticles as a Multifunctional Nanomedicine to Promote Macrophage Efferocytosis and Repolarization for Atherosclerosis Therapy. [Abstract]

2023 Nov 15;15(45):52162-52179. PMID: 37910772
Free Radic Biol Med

Ferroptosis was more initial in cell death caused by iron overload and its underlying mechanism in Parkinson's disease. [Abstract]

2020 May 20;152:227-234. PMID: 32217194
Drug Deliv

Reliable high-PAP-1-loaded polymeric micelles for cancer therapy: preparation, characterization, and evaluation of anti-tumor efficacy. [Abstract]

2025 Dec;32(1):2490269. PMID: 40207975
Biomed Pharmacother

Homoharringtonine (omacetaxine mepesuccinate) limits the angiogenic capacity of endothelial cells and reorganises filamentous actin. [Abstract]

2025 Apr 3:186:118025. PMID: 40184838
J Transl Med

OPA1 mutations in dominant optic atrophy: domain-specific defects in mitochondrial fusion and apoptotic regulation. [Abstract]

2025 Apr 24;23(1):471. PMID: 40275276
Biomed Pharmacother

Polypharmacological profiling across protein target families and cellular pathways using the multiplexed cell-based assay platform safetyProfiler reveals efficacy, potency and side effects of drugs. [Abstract]

2024 Nov:180:117523. PMID: 39405910
Oncogene

DNA replication stress and translational repression converge to drive CDK1- and caspase-dependent apoptosis in Ewing sarcoma. [Abstract]

2026 Jun 10. PMID: 42270776
Stem Cell Res Ther

hPDLSC-ApoEVs attenuate periodontitis and enhance bone regeneration via NF-κB/S100A9-Mediated M2 macrophage polarization. [Abstract]

2025 Sep 26;16(1):508. PMID: 41013784
Cell Chem Biol

Identifying enhancers of innate immune signaling as broad-spectrum antivirals active against emerging viruses. [Abstract]

2022 Jul 21;29(7):1113-1125.e6. PMID: 35728599
Blood Adv

CBFA2T3::GLIS2 Pediatric Acute Megakaryoblastic Leukemia is Sensitive to BCL-XL Inhibition by Navitoclax and DT2216. [Abstract]

2024 Jan 9;8(1):112-129. PMID: 37729615
Cell Death Discov

Crizotinib and its enantiomer suppress ferroptosis by decreasing PE-O-PUFA content. [Abstract]

2024 Aug 12;10(1):360. PMID: 39134539
Cell Death Discov

Sirtuin 6 is a key contributor to gender differences in acute kidney injury. [Abstract]

2023 Apr 25;9(1):134. PMID: 37185276
Cell Death Discov

Reduced osteoclast-derived apoptotic bodies in bone marrow characterizes the pathological progression of osteoporosis. [Abstract]

2023 Apr 26;9(1):135. PMID: 37185334
Cell Death Discov

TRIB2 desensitizes ferroptosis via βTrCP-mediated TFRC ubiquitiantion in liver cancer cells. [Abstract]

2021 Jul 27;7(1):196. PMID: 34315867
Cell Rep

ISG15 negatively regulates RIPK3-mediated cell death and viral pathogenesis. [Abstract]

2026 May 26;45(5):117360. PMID: 42139056
Food Front

2025 Aug 19.
Cell Rep

Vault RNAs aid RNA virus infection by facilitating cytoplasmic localization of hnRNP C and ELAVL1. [Abstract]

2025 Jun 12;44(6):115823. PMID: 40512618
Cell Rep

Targeting high circDNA2v levels in colorectal cancer induces cellular senescence and elicits an anti-tumor secretome. [Abstract]

2024 Apr 23;43(4):114111. PMID: 38615319
Cell Rep

The tetrapeptide sequence of IL-18 and IL-1β regulates their recruitment and activation by inflammatory caspases. [Abstract]

2023 Dec 15;42(12):113581. PMID: 38103201
Cell Rep

SFTSV Infection Induces BAK/BAX-Dependent Mitochondrial DNA Release to Trigger NLRP3 Inflammasome Activation. [Abstract]

2020 Mar 31;30(13):4370-4385.e7. PMID: 32234474
J Med Chem

Discovery of APS03118, a Potent and Selective Next-Generation RET Inhibitor with a Novel Kinase Hinge Scaffold. [Abstract]

2025 Sep 25;68(18):19536-19553. PMID: 40920215
J Med Chem

Identification of Benzofuro[2,3- b]pyridine Pseudonatural Product as a Novel Class of Ferritinophagy Inhibitors that Potently Suppress Ferroptosis. [Abstract]

2025 Aug 25. PMID: 40853144
Antioxidants (Basel)

Analysis of High-Dose Ascorbate-Induced Cytotoxicity in Human Glioblastoma Cells and the Role of Dehydroascorbic Acid and Iron. [Abstract]

2024 Sep 10;13(9):1095. PMID: 39334754
Sci Signal

Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics. [Abstract]

2021 Jun 8;14(686):eabc7405. PMID: 34103421
Oncogenesis

Tumor suppressor BAP1 suppresses disulfidptosis through the regulation of SLC7A11 and NADPH levels. [Abstract]

2024 Sep 12;13(1):31. PMID: 39266549
EMBO Rep

Loss of the lysosomal protein CLN3 triggers c-Abl-dependent YAP1 pro-apoptotic signaling. [Abstract]

2025 Nov 6. PMID: 41198904
EPMA J

Glioma angiogenesis phosphoproteome landscape and biomarker sets identified with phenome-centered multiomics toward 3P medical approaches. [Abstract]

2025 Nov 3;16(4):831-856. PMID: 41312000
Eur J Med Chem

Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. [Abstract]

2019 Nov 1:181:111552. PMID: 31387063
Pharmaceutics

The Activity of FDA-Approved Prodrug Isavuconazonium Sulfate and Its Major Metabolite Isavuconazole Against Naegleria fowleri. [Abstract]

2026 Jan 12;18(1):103. PMID: 41599210
J Ethnopharmacol

Mechanistic exploration of Dahuang Zhechong Pill against hepatic fibrosis via integrated serum pharmacochemistry, UHPLC-ESI-QTOF-MS/MS, network pharmacology, and molecular docking with cellular and zebrafish validation. [Abstract]

2025 Jul 24:351:120102. PMID: 40480395
Cells

TRPV4 Deficiency Shifts Mitochondrial Dynamics Toward a Fragmented Morphology in Primary Microglia. [Abstract]

2026 Feb 13;15(4):341. PMID: 41744784
Cells

A Comprehensive Adenoid Cystic Carcinoma-Derived Organoid Platform for Disease Modeling and Drug Screening Captures Interpatient Heterogeneity. [Abstract]

2026 Feb 23;15(4):383. PMID: 41744826
Cells

Lipophilic Statins Eliminate Senescent Endothelial Cells by inducing Anoikis-Related Cell Death. [Abstract]

2023 Dec 14;12(24):2836. PMID: 38132158
Commun Biol

Aggressive breast cancers secrete heme metabolites to alter macrophage immune suppression and function. [Abstract]

2026 May 9. PMID: 42106562
Life Sci

LC3B/p62-mediated mitophagy protects A549 cells from resveratrol-induced apoptosis. [Abstract]

2021 Apr 15:271:119139. PMID: 33539914
PLoS Pathog

Cell death modulation dictates tissue-specific tropism of lumpy skin disease virus. [Abstract]

2026 Feb 26;22(2):e1013982. PMID: 41746912
Int J Mol Sci

Apoptotic Caspases-3 and -7 Cleave Extracellular Domains of Membrane-Bound Proteins from MDA-MB-231 Breast Cancer Cells. [Abstract]

2025 Apr 8;26(8):3466. PMID: 40331965
PLoS Pathog

RVFV virulence factor NSs triggers the mitochondrial MCL-1-BAK axis to activate pathogenic NLRP3 pyroptosis. [Abstract]

2024 Aug 30;20(8):e1012387. PMID: 39213434
Int J Mol Sci

High CD142 Level Marks Tumor-Promoting Fibroblasts with Targeting Potential in Colorectal Cancer. [Abstract]

2023 Jul 18;24(14):11585. PMID: 37511344
Front Pharmacol

Identification of solamargine as a cisplatin sensitizer through phenotypical screening in cisplatin-resistant NSCLC organoids. [Abstract]

2022 Aug 10:13:802168. PMID: 36034794
Bioorg Chem

Discovery of novel benzo[b][1,4]oxazine derivatives as ferroptosis inhibitors. [Abstract]

2025 Jan 23:156:108201. PMID: 39864374
Int J Cancer

GNAS mutation inhibits growth and induces phosphodiesterase 4D expression in colorectal cancer cell lines. [Abstract]

2024 Jun 1;154(11):1987-1998. PMID: 38319157
mBio

Herpes Simplex Virus 1-Induced Ferroptosis Contributes to Viral Encephalitis. [Abstract]

2023 Feb 28;14(1):e0237022. PMID: 36507835
Eur J Pharmacol

Novel vandetanib derivative inhibited proliferation and promoted apoptosis of cancer cells under normoxia and hypoxia. [Abstract]

2022 May 5:922:174907. PMID: 35331723
Int Immunopharmacol

Aldose reductase inhibitors attenuate β-amyloid-induced TNF-α production in microlgia via ROS-PKC-mediated NF-κB and MAPK pathways. [Abstract]

2017 Sep:50:30-37. PMID: 28623716

Staurosporine purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2017 Sep:50:30-37. [Abstract]

BV-2 cells are pretreated with or without Staurosporine (1 μM) for 30 min, and then incubated with 20 μM Aβ_1–42 for 24 h. The protein expression of TNF-α, IL-1β, and IL-6 are detected by western blot.
J Med Virol

Borna disease virus 1 induces ferroptosis, contributing to lethal encephalitis. [Abstract]

2024 Oct;96(10):e29945. PMID: 39370874
Molecules

The Difference in Cytotoxic Activity between Two Optical Isomers of Gelsemine from Gelsemium elegans Benth. on PC12 Cells. [Abstract]

2019 May 25;24(10):2004. PMID: 31130596
Mol Oncol

ERBB and P-glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P-glycoprotein. [Abstract]

2023 Jan;17(1):37-58. PMID: 36181342
Cancers (Basel)

Cytotoxic Autophagy: A Novel Treatment Paradigm against Breast Cancer Using Oleanolic Acid and Ursolic Acid. [Abstract]

2024 Oct 1;16(19):3367. PMID: 39409987
Cancers (Basel)

Enhancer of Zeste Homolog 2 Protects Mucosal Melanoma from Ferroptosis via the KLF14-SLC7A11 Signaling Pathway. [Abstract]

2024 Oct 30;16(21):3660. PMID: 39518098
Ann Med

Apoptotic body-encapsulated nanoparticles regulate inflammation through macrophage polarization mediated by lactic acid. [Abstract]

2026 Dec;58(1):2624211. PMID: 41664606
Mol Neurobiol

3-n-Butylphthalide Protects SH-SY5Y Cells from Ferroptosis by Inhibiting ACSL4-Mediated Lipid Peroxidation. [Abstract]

2026 Jan 16;63(1):369. PMID: 41545774
Mol Neurobiol

Cholesterol and 24S-OHC Induce Neuronal Apoptosis and Necroptosis, but Not Ferroptosis Despite Elevated Iron Levels. [Abstract]

2025 Sep 18. PMID: 40968333
ACS Bio Med Chem Au

A Potent Inhibitor of Caspase‑8 Based on the IL-18 Tetrapeptide Sequence Reveals Shared Specificities between Inflammatory and Apoptotic Initiator Caspases. [Abstract]

2025 Jul 2;5(4):565-581. PMID: 40860029
Structure

PROTAC-mediated activation, rather than degradation, of a nuclear receptor reveals complex ligand-receptor interaction network. [Abstract]

2024 Dec 5;32(12):2352-2363.e8. PMID: 39389062
Poult Sci

PKA and PKC signaling pathways mediate vitamin D₃-regulated intestinal phosphorus absorption in broiler chickens. [Abstract]

2026 Mar 12;105(6):106762. PMID: 41855802
J Mol Med (Berl)

Cerium oxide nanoparticles as potent inhibitors of ferroptosis: role of antioxidant activity and protein regulation. [Abstract]

2025 Jul;103(7):849-866. PMID: 40448735
J Cell Mol Med

BRAF V600E protect from cell death via inhibition of the mitochondrial permeability transition in papillary and anaplastic thyroid cancers. [Abstract]

2022 Jul;26(14):4048-4060. PMID: 35748101
J Cell Mol Med

The outer membrane protein Tp92 of Treponema pallidum induces human mononuclear cell death and IL-8 secretion. [Abstract]

2018 Dec;22(12):6039-6054. PMID: 30596396
Toxicol Sci

Stress-activated pathways mediate PFAS effects on human placental syncytiotrophoblast cells. [Abstract]

2026 Jun 5;209(6):kfag060. PMID: 42172632
iScience

STEMIN- and YAP5SA-induced exosomes prevent cardiomyocyte apoptosis. [Abstract]

2026 Jun 22;29(7):116277. PMID: 42383000
iScience

Effect of mitophagy in the formation of osteomorphs derived from osteoclasts. [Abstract]

2023 Apr 18;26(5):106682. PMID: 37250312
iScience

Small molecule SJ572946 activates BAK to initiate apoptosis. [Abstract]

2022 Sep 6;25(10):105064. PMID: 36147946
Virol Sin

Identification of a novel caspase cleavage motif AEAD. [Abstract]

2024 Aug 2:S1995-820X(24)00115-9. PMID: 39098717
Oncol Rep

Role of iron and TfR1 in the application of high‑dose ascorbate against pancreatic cancer. [Abstract]

2026 Apr;55(4):78. PMID: 41789665
Sci Rep

Neuronal growth patterns and synapse formation are mediated by distinct activity-dependent mechanisms. [Abstract]

2025 May 19;15(1):17338. PMID: 40389417
J Biol Chem

The structures of salt inducible kinase 3 in complex with pharmacological inhibitors reveal determinants for binding and selectivity. [Abstract]

2024 May;300(5):107201. PMID: 38508313
Sci Rep

ACSS2-mediated NF-κB activation promotes alkaliptosis in human pancreatic cancer cells. [Abstract]

2023 Jan 27;13(1):1483. PMID: 36707625
Fish Shellfish Immunol

Functional characterization of a putative lipopolysaccharide-induced TNF-alpha factor (LITAF) from blood clam Tegillarca granosa in innate immunity. [Abstract]

2020 Feb;97:390-402. PMID: 31866450
Sci Rep

Identification of a DYRK1A Inhibitor that Induces Degradation of the Target Kinase using Co-chaperone CDC37 fused with Luciferase nanoKAZ. [Abstract]

2015 Aug 3;5:12728. PMID: 26234946
J Virol

TGF-β inhibitor SB431542 suppresses SARS-CoV-2 replication through multistep inhibition. [Abstract]

2025 Aug 29:e0052925. PMID: 40879372
J Virol

The African swine fever virus MGF360-16R protein functions as a mitochondrial-dependent apoptosis inducer by competing with BAX to bind to the HSP60 protein. [Abstract]

2025 Apr 15;99(4):e0140124. PMID: 40013993
ACS Chem Biol

A Class of Disulfide Compounds Suppresses Ferroptosis by Stabilizing GPX4. [Abstract]

2022 Dec 16;17(12):3389-3406. PMID: 36446024
J Virol

The role of lysosomes as intermediates in betacoronavirus PHEV egress from nerve cells. [Abstract]

2023 Dec 21;97(12):e0133823. PMID: 38009916
Chem Res Toxicol

Bisdemethoxycurcumin Protection of Cardiomyocyte Mainly Depends on Nrf2/HO-1 Activation Mediated by the PI3K/AKT Pathway. [Abstract]

2019 Sep 16;32(9):1871-1879. PMID: 31402651
ACS Chem Biol

A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family. [Abstract]

2017 May 19;12(5):1245-1256. PMID: 28263556
Brain Res Bull

Multi-omics analysis reveals the protective role of transcriptional enhancer factor and the pathogenic mechanism of monocytes in Parkinson's disease. [Abstract]

2025 Oct 22:232:111594. PMID: 41135742
Cell Signal

AMPK impairment caused by gelatin disturbs mitochondrial dynamics leading to enhanced phagocytosis of bacteria in PMA-stimulated U937 cells. [Abstract]

2025 Nov:135:111985. PMID: 40653043
Biochim Biophys Acta

Nogo-B (Reticulon-4B) functions as a negative regulator of the apoptotic pathway through the interaction with c-FLIP in colorectal cancer cells. [Abstract]

2018 Aug;1864(8):2600-2609. PMID: 29684585

Staurosporine purchased from MedChemExpress. Usage Cited in: Biochim Biophys Acta. 2018 Aug;1864(8):2600-2609. [Abstract]

Expression of Nogo-B and apoptosis-related proteins determined by Western blot analysis.
Development

Clathrin-mediated endocytosis is essential for the selective degradation of maternal membrane proteins and preimplantation development. [Abstract]

2021 Jul 15;148(14):dev199461. PMID: 34269385
Regen Ther

Apoptotic vesicles inhibit bone marrow adiposity via wnt/β-catenin signaling. [Abstract]

2025 Mar 28:29:262-270. PMID: 40230357
ChemMedChem

Novel Indoline Derivatives as Ferroptosis Inhibitors: Synthesis, Biological Evaluation, and Mechanistic Investigation. [Abstract]

2025 Aug 18:e202500487. PMID: 40824902
Future Med Chem

Discovery of novel dual VEGFR2 and Src inhibitors using a multistep virtual screening approach. [Abstract]

2017 Jan;9(1):7-24. PMID: 27995811
Cytotherapy

Clinically compliant cryopreservation of differentiated retinal pigment epithelial cells. [Abstract]

2024 Apr;26(4):340-350. PMID: 38349309
BMC Oral Health

Apoptotic extracellular vesicles derived from human dental pulp stem cells facilitate periodontal tissue regeneration. [Abstract]

2025 Jul 11;25(1):1150. PMID: 40646544
Front Biosci (Landmark Ed)

Influence of RRM, RGG and Potential Phosphorylated Sites in Cold-Inducible Protein RBM3 on its Subcellular Localization and Neuroprotective Effects. [Abstract]

2023 Feb 8;28(2):24. PMID: 36866549
Mol Inform

Development of Ligand-based Big Data Deep Neural Network Models for Virtual Screening of Large Compound Libraries. [Abstract]

2018 Nov;37(11):e1800031. PMID: 29882343
Med Chem Res

2017, 26(9), 2007-2014.
Bioorg Med Chem

D-DARTS: an alternative method for NaV1.5 affinity molecules identification based on dual-drug affinity responsive target stability. [Abstract]

2025 Oct 9:132:118436. PMID: 41086654
Arch Biochem Biophys

Silibinin-induced apoptosis of breast cancer cells involves mitochondrial impairment. [Abstract]

2019 Aug 15:671:42-51. PMID: 31085166
J Biomed Opt

Label-free fluorescence lifetime imaging for the assessment of cell viability in living tumor fragments. [Abstract]

2024 Jun;29(Suppl 2):S22709. PMID: 38881557
Neuroscience

Sonic hedgehog induces GLT-1 degradation via PKC delta to suppress its transporter activities. [Abstract]

2017 Dec 4:365:217-225. PMID: 28993237

Staurosporine purchased from MedChemExpress. Usage Cited in: Neuroscience. 2017 Dec 4:365:217-225. [Abstract]

PMA markedly reduces the protein level of GLT-1.
Clin Transl Radiat Oncol

In vitro determination of patient-specific variation challenges the universal RBE gold standard for proton radiation therapy. [Abstract]

2025 Sep 15:56:101046. PMID: 41049395
SLAS Discov

High-throughput evaluation of novel WRN inhibitors. [Abstract]

2025 Aug 25:35:100266. PMID: 40865724
Virus Res

Characteristics of enterovirus 71-induced cell death and genome scanning to identify viral genes involved in virus-induced cell apoptosis. [Abstract]

2019 May:265:104-114. PMID: 30910697
PLoS One

A novel small molecule screening assay using normal human chondrocytes toward osteoarthritis drug discovery. [Abstract]

2024 Nov 1;19(11):e0308647. PMID: 39485774
Tissue Cell

PGC1α enhances macrophage efferocytosis in ox-LDL-stimulated RAW264.7 cells by regulating the NLRP3/PPARα axis. [Abstract]

2024 Oct:90:102476. PMID: 39047550
Biochem Biophys Res Commun

Interaction of CDK12 with NXF1 is a new node for the linking mechanism between transcription and transportation of mRNA. [Abstract]

2024 Aug 28:735:150608. PMID: 39270556
Bioorg Med Chem Lett

Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes. [Abstract]

2019 Feb 15;29(4):549-555. PMID: 30630717
Biochem Biophys Res Commun

Effects of intracellular iron overload on cell death and identification of potent cell death inhibitors. [Abstract]

2018 Sep 3;503(1):297-303. PMID: 29890135
Indian J Ophthalmol

Ranitidine protects Müller cells against ferroptosis in diabetic retinopathy by regulating the AKT1/GSK3β pathway. [Abstract]

2026 Feb 1;74(2):250-258. PMID: 41581041
Vet Comp Oncol

Oncolytic activity of canine distemper virus in canine mammary tubular adenocarcinoma cells. [Abstract]

2019 Jun;17(2):174-183. PMID: 30756476
Anticancer Res

TLK1 Inhibition Enhances the Anticancer Effect of Deep UV Irradiation Through CHK1 Activation. [Abstract]

2024 Jul;44(7):2827-2836. PMID: 38925844
Res Sq

2026 Feb 24.
University of Debrecen

2023.
bioRxiv

2026 Feb 25.
bioRxiv

Hidden-driver inference reveals synergistic brain-penetrant therapies for medulloblastoma. [Abstract]

2025 Nov 20:2025.11.20.689490. PMID: 41332625
bioRxiv

2025 Oct 28.
bioRxiv

2025 Nov 27.
bioRxiv

2025 Sep 17.
bioRxiv

2025 Sep 21.
SSRN

2025 Jul 26.
Seoul National University

2025.
bioRxiv

Hepatocyte expression of fetal insulin receptor isoform contributes to the promotion of liver cancer through non-cell autonomous mechanisms. [Abstract]

2025 Jun 5:2025.06.02.655477. PMID: 40502023
bioRxiv

2025 May 30.
Patent

US20250161319A1.
bioRxiv

2025 April 17.
bioRxiv

2025 April 15.
bioRxiv

Chemical Tools Based on the Tetrapeptide Sequence of IL-18 Reveals Shared Specificities between Inflammatory and Apoptotic Initiator Caspases. [Abstract]

2025 Feb 27:2025.02.23.639785. PMID: 40060427
bioRxiv

2025 March 21.
Res Sq

2025 Feb 16.
Research Square Preprint

2025 Jan 08.
Res Sq

2024 Aug 29.
bioRxiv

Low-Cost Robotic Manipulation of Live Microtissues for Cancer Drug Testing. [Abstract]

2024 Aug 6:2024.03.21.586169. PMID: 38586030
bioRxiv

Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity. [Abstract]

2024 Aug 1:2024.08.01.605889. PMID: 39211113
bioRxiv

2024 July 14.
Karolinska Institute

2024 Apr 22.
SSRN

2023 Sep 29.
bioRxiv

2023 Sep 5.
Patent

US20230190773A1.
bioRxiv

2023 Apr 14.
bioRxiv

2023 Feb 28.
Patent

US20230075765A1.
Ruprecht Karls University

2023 Feb 2.
SSRN

2022 Nov 21.
Research Square Print

October 27th, 2022.
Research Square Preprint

2022 Jul.
Research Square Preprint

2022 Jun.
Research Square Preprint

2022 Feb.
Patent

US20220016148A1.
Patent

US20210379056A1.
Chinese Pharmacological Bulletin

2017, 33(12): 1661-1667.

Solvent & Solubility

In Vitro:

DMSO : 62.5 mg/mL (133.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1435 mL

10.7174 mL

21.4348 mL

5 mM

0.4287 mL

2.1435 mL

4.2870 mL

10 mM

0.2143 mL

1.0717 mL

2.1435 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.46 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (4.46 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.46 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: 3.33 mg/mL (7.14 mM); Suspension solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Animal Administration^[3]^[4]

Mice^[3]
Female CD-I mice are used. Various amounts of Staurosporine in 10 μL of acetone are applied to the ears of 8-wk-old CD-I mice. The extent of irritation is expressed as the minimum dose of the compound causing irritation. Induction of HOC in Mouse Skin Staurosporine in 0.1 mL of acetone is applied to the skin of the backs of CD-I mice, and a crude enzyme extract is obtained from the skin 18 h later. HDC activity is expressed as pmol of CO₂ released per mg of protein per l h of incubation. Induction of ODC in Mouse Skin Staurosporine in 0.2 mL of acetone is applied to the skin of the backs of CD-I mice. After 4 h, a crude enzyme extract is prepared from the epidermis, and its ODC activity is measured. Enzyme activity is expressed as nmol of CO₂ per mg of protein per 30 min of incubation.
Rats^[4]
Male Kbl Wistar rats(weighing 270 to 310 g) are used. In the group which is given Staurosporine for 2 weeks, the water maze task and Staurosporine administration are started 2 weeks after the BF-lesion, and the passive avoidance task is carried out 4 weeks after the BFlesion. The rat received Staurosporine at doses of 0.01, 0.03, 0.1, and 0.3 mg/kg (i.p., N=10 in each group for 2 weeks) 30 mm prior to the water maze training sessions and the passive avoidance task acquisitiontrial. In the group which is given Staurosporine for 4 weeks, the drug is first given 2 weeks after the BF-lesion. The water maze task is carried out 4 weeks after the BF-lesion. The passive avoidance task is carried out 6 weeks after the BF-lesion. The rat received Staurosporine at 0.05, 0.1, and 0.2 mg/kg (i.p., N=10 in each group) once a day for 2 weeks before training, and for 2 weeks after the water maze training sessions and the passive avoidance task acquisition trial. Staurosporine is suspended in 0.3% of sodium carboxymethyl cellulose. The vehicle is administered to the non-lesioned controls and the lesioned controls on the same schedule as the Staurosporine-treated animals.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (296 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Meggio F, et al. Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur J Biochem. 1995 Nov 15;234(1):317-22. [Content Brief]

[2]. Chae HJ, et al. Molecular mechanism of staurosporine-induced apoptosis in osteoblasts. Pharmacol Res. 2000 Oct;42(4):373-81. [Content Brief]

[3]. Yoshizawa S, et al. Tumor-promoting activity of staurosporine, a protein kinase inhibitor on mouse skin.Cancer Res. 1990 Aug 15;50(16):4974-8. [Content Brief]

[4]. Nabeshima T, et al. Staurosporine facilitates recovery from the basal forebrain-lesion-induced impairment of learning and deficit of cholinergic neuron in rats. J Pharmacol Exp Ther. 1991 May;257(2):562-6. [Content Brief]

[5]. Yujie Ren, et al. The ORF3a Protein of SARS-CoV-2 Induces Apoptosis in Cells. Cell Mol Immunol. 2020 Jun 18;1-3. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1435 mL	10.7174 mL	21.4348 mL	53.5871 mL
	5 mM	0.4287 mL	2.1435 mL	4.2870 mL	10.7174 mL
	10 mM	0.2143 mL	1.0717 mL	2.1435 mL	5.3587 mL
	15 mM	0.1429 mL	0.7145 mL	1.4290 mL	3.5725 mL
	20 mM	0.1072 mL	0.5359 mL	1.0717 mL	2.6794 mL
	25 mM	0.0857 mL	0.4287 mL	0.8574 mL	2.1435 mL
	30 mM	0.0714 mL	0.3572 mL	0.7145 mL	1.7862 mL
	40 mM	0.0536 mL	0.2679 mL	0.5359 mL	1.3397 mL
	50 mM	0.0429 mL	0.2143 mL	0.4287 mL	1.0717 mL
	60 mM	0.0357 mL	0.1786 mL	0.3572 mL	0.8931 mL
	80 mM	0.0268 mL	0.1340 mL	0.2679 mL	0.6698 mL
	100 mM	0.0214 mL	0.1072 mL	0.2143 mL	0.5359 mL

Keywords

Staurosporine

214 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Staurosporine

Anti-Infection Compound Library

Apoptosis Compound Library

Epigenetics Compound Library

Kinase Inhibitor Library

Stem Cell Signaling Compound Library

TGF-beta/Smad Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Antifungal Compound Library

Antibacterial Compound Library

Cytoskeleton Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Alkaloids Library

Microbial Metabolite Library

Neurodegenerative Disease-related Compound Library

Anti-Cancer Natural Product Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Coagulation and Anti-coagulation Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Marine-Sourced Natural Product Library

Membrane Protein-targeted Compound Library

Mitochondrial Toxicity Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Multi-Target Compound Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

Kinase Inhibitor Library Mini

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Posttranslational Modification Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Bacteria-Sourced Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Staurosporine

All PKC Isoforms

All PKA Isoforms

All Antibiotic Isoforms

Biological Activity

Chemical Information

Publications (214)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Staurosporine Related Classifications

Cat. No.: HY-15141